Covered_Recipient_Type,Teaching_Hospital_ID,Teaching_Hospital_Name,Physician_Profile_ID,Physician_First_Name,Physician_Middle_Name,Physician_Last_Name,Recipient_Primary_Business_Street_Address_Line1,Recipient_Primary_Business_Street_Address_Line2,Recipient_City,Recipient_Zip_Code,Physician_Primary_Type,Physician_Specialty,Submitting_Applicable_Manufacturer_or_Applicable_GPO_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750699,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750700,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750702,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,7820.00,12/20/2013,Cash or cash equivalent,105750708,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754898,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754901,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,2432.00,11/01/2013,Cash or cash equivalent,105754923,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754757,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754769,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754787,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750703,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,304.00,11/12/2013,Cash or cash equivalent,105750707,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,449,TRINITY MEDICAL CENTER,,,,,4500 UTICA RIDGE RD,,BETTENDORF,52722,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,2775.00,11/19/2013,Cash or cash equivalent,105731579,EFFIENT,,THE TRANSLATE ACS STUDY - TREATMENT WITH ADP RECEPTOR INHIBITORS -  LONGITUDINAL ASSESSMENT OF TREATMENT PATTERNS AND EVENTS AFTER ACUTE CORONARY SYNDROME,http://clinicaltrials.gov/ct2/show/NCT01088503,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,6855.57,12/31/2013,In-kind items and services,105732553,HUMALOG,,TWO TREATMENT APPROACHES FOR HUMAN REGULAR U500 INSULIN - THRICE DAILY VERSUS TWICE DAILY - IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS - A RANDOMIZED OPEN LABEL PARALLEL CLINICAL TRIAL,http://clinicaltrials.gov/ct2/show/NCT01774968,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,91432.00,08/06/2013,Cash or cash equivalent,105732563,HUMALOG,,TWO TREATMENT APPROACHES FOR HUMAN REGULAR U500 INSULIN - THRICE DAILY VERSUS TWICE DAILY - IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS - A RANDOMIZED OPEN LABEL PARALLEL CLINICAL TRIAL,http://clinicaltrials.gov/ct2/show/NCT01774968,
Non-covered Recipient Entity,,,,,,,513 N Cherry St,Null,Shell Rock,50670,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,5018.00,12/20/2013,Cash or cash equivalent,105764340,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750704,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/01/2013,Cash or cash equivalent,105754749,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754761,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754762,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754764,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754778,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754780,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754782,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754893,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754904,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,404.00,11/01/2013,Cash or cash equivalent,105754915,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,404.00,11/01/2013,Cash or cash equivalent,105754916,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750698,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750701,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105750705,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,304.00,11/12/2013,Cash or cash equivalent,105750706,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754751,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754753,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754760,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,513 N Cherry St,Null,Shell Rock,50670,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,89.00,12/27/2013,Cash or cash equivalent,105764339,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754763,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754774,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754783,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754891,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754897,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754903,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754905,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,726.00,11/01/2013,Cash or cash equivalent,105754920,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754909,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754910,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754912,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,513 N Cherry St,Null,Shell Rock,50670,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,89.00,12/27/2013,Cash or cash equivalent,105764338,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,100.00,11/01/2013,Cash or cash equivalent,105754747,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754752,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754766,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754768,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754773,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754775,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754907,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754754,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754755,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754756,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754758,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754781,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754785,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754895,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754765,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754772,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754786,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754899,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754908,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,404.00,11/01/2013,Cash or cash equivalent,105754918,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,726.00,11/01/2013,Cash or cash equivalent,105754919,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/01/2013,Cash or cash equivalent,105754750,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754779,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754788,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754906,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754913,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754914,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,404.00,11/01/2013,Cash or cash equivalent,105754917,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,61533.00,12/20/2013,Cash or cash equivalent,105754924,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,11705.20,12/05/2013,Cash or cash equivalent,105892522,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase #BTK# Inhibitor, in Combination with Bendamustine and Rituximab #BR# in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia#Small Lymphocytic Lymphoma",,
Non-covered Recipient Entity,,,,,,,5B JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,164808.00,11/08/2013,Cash or cash equivalent,105895384,Invega,Invega Sustenna,Effects of Paliperidone Palmitate vs Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients#  A Randomized Clinical Trial,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702-5014,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3840.00,09/27/2013,Cash or cash equivalent,105893770,No Product,,Outcomes Registry of Better Quality of Care In the Treatment #ORBIT# Atrial Fibrillation Registry.,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,Grant Accounting Office,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,8000.00,10/10/2013,In-kind items and services,105892519,Yondelis,,ET743-SAR-3002,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,588.00,10/04/2013,Cash or cash equivalent,105892520,Yondelis,,A Randomized Controlled Study of YONDELIS #trabectedin# or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,100.00,11/01/2013,Cash or cash equivalent,105754748,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754759,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754767,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754770,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754771,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754776,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754777,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754784,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754789,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754890,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754892,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754894,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754896,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754900,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754902,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,105754911,,,DU176b-C-U301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1782.00,11/01/2013,Cash or cash equivalent,105754921,,,DU176b-E-U210,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,2432.00,11/01/2013,Cash or cash equivalent,105754922,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,2500.00,08/21/2013,Cash or cash equivalent,105920176,Menveo,,"Immunogenecity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 to 10 Years of Age",,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,1701.00,11/06/2013,Cash or cash equivalent,105920153,Menveo,,"Immunogenecity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 to 10 Years of Age",,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503,,,Novartis Vaccines and Diagnostics Inc,100000000209,Novartis Vaccines and Diagnostics Inc,MA,5506.20,08/07/2013,Cash or cash equivalent,105920179,Menveo,,"Immunogenecity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 to 10 Years of Age",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,2790.00,12/15/2013,Cash or cash equivalent,106210152,,,YA-OSS-0003,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,529.00,10/03/2013,Cash or cash equivalent,106210155,,,D-2003-003,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,48163.00,10/25/2013,Cash or cash equivalent,106210158,,,D-2012-036,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,10000.00,10/24/2013,Cash or cash equivalent,106210147,,,D-2012-036,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,18400.00,11/25/2013,Cash or cash equivalent,106210148,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,5 W Jefferson St,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,58791.03,11/06/2013,Cash or cash equivalent,106143959,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010-12,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Drive SE 512 Gh,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,90.00,10/18/2013,Cash or cash equivalent,106143897,,,MM PAS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,5 W Jefferson St,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,17122.27,08/28/2013,Cash or cash equivalent,106143911,,,The PARTNER II Trial Placement of Aortic Transcatheter Valve Trial 2010-12,,
Non-covered Recipient Entity,,,,,,,601 HIGHWAY 6 WEST,,IOWA CITY,52246,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,14800.00,09/27/2013,Cash or cash equivalent,106215718,Anti-Bacterial,,LCD CDAD 11 06 2013 37,,
Non-covered Recipient Entity,,,,,,,1241 8th Street,,West Des Moines,50265,,,Cubist Pharmaceuticals Inc,100000010606,Cubist Pharmaceuticals Inc,MA,7152.25,09/24/2013,Cash or cash equivalent,106215144,Gastrointestinal,,5945 OIC 12 05 2013 118,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,5 W Jefferson St,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,42051.25,11/27/2013,Cash or cash equivalent,106143969,,,MM PAS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,3200.00,12/15/2013,Cash or cash equivalent,106210151,,,YA-SHO-0001,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTPSLY IH AB,100000010687,DENTPSLY IH AB,PA,1300.00,12/15/2013,Cash or cash equivalent,106210154,,,D-2009-043,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403-2414,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6020.00,08/01/2013,In-kind items and services,105893772,Sirukumab,,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 #sirukumab#, a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,13095.00,08/23/2013,Cash or cash equivalent,105892521,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase #BTK# Inhibitor, in Combination with Bendamustine and Rituximab #BR# in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,8585.00,08/03/2013,Cash or cash equivalent,106036352,NON_BRAND,,A RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED  PARALLEL GROUP STUDY EVALUATING THE EFFICACY  SAFETY  PHARMACOKINETICS AND PHARMACODYNAMICS OF QGE031 IN THE TREATMENT OF PATIENTS WITH BULLOUS PEMPHIGOID WITH DISEASE REFRACTORY TO ORAL STEROID TREATMENT,,
Covered Recipient Teaching Hospital,578,Northwest Iowa Hospital Corporation,,,,,2720 Stone Park Blvd,,Sioux City,51104,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3000.00,08/12/2013,Cash or cash equivalent,105892518,Yondelis,,A Randomized Controlled Study of YONDELIS #trabectedin# or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403-2414,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4896.00,08/09/2013,In-kind items and services,105893771,Sirukumab,,"Vaccine Response Substudy of# A Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel Group Study of CNTO 136 #sirukumab#, a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2170.00,10/28/2013,In-kind items and services,105894526,Remicade,,"Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE #infliximab# and Placebo in the Prevention of Relapse in Crohns Disease Patients Undergoing Surgical Resection",,
Non-covered Recipient Entity,,,,,,,207 CROCKER ST,STE 300,DES MOINES,50309-1318,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,8775.00,12/17/2013,Cash or cash equivalent,106032985,,,PERSEUS WORKHORSE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,10136.25,11/18/2013,Cash or cash equivalent,106033324,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA PAS2,,
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803-2459,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,375.00,09/13/2013,Cash or cash equivalent,106030943,,,MV Calibration Study Determination of Short term variability of the MV signal,,
Covered Recipient Teaching Hospital,569,St Lukes Methodist Hospital,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,525.00,11/28/2013,Cash or cash equivalent,106032743,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,4016.25,08/08/2013,Cash or cash equivalent,106033321,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA PAS2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,1846.25,10/07/2013,Cash or cash equivalent,106033323,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA PAS2,,
Covered Recipient Teaching Hospital,569,St Lukes Methodist Hospital,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,3843.22,09/13/2013,Cash or cash equivalent,106032740,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,569,St Lukes Methodist Hospital,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,550.00,08/16/2013,Cash or cash equivalent,106032739,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,569,St Lukes Methodist Hospital,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,1096.61,10/07/2013,Cash or cash equivalent,106032741,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,569,St Lukes Methodist Hospital,,,,,1026 A Ave NE,,Cedar Rapids,52402,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,550.00,11/28/2013,Cash or cash equivalent,106032742,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Non-covered Recipient Entity,,,,,,,600 7th Stree SE,,Cedar Rapids,52401,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,500.00,10/04/2013,Cash or cash equivalent,105985716,,,Global Regenerex Tibial Tray Study,,
Non-covered Recipient Entity,,,,,,,600 7th Stree SE,,Cedar Rapids,52401,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,7500.00,10/11/2013,Cash or cash equivalent,105985569,,,Vanguard Midterm Publication and Echo Hip System White Paper,,
Non-covered Recipient Entity,,,,,,,207 CROCKER ST,STE 300,DES MOINES,50309-1318,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,600.00,10/07/2013,Cash or cash equivalent,106032984,,,PLATINUM,,
Non-covered Recipient Entity,,,,,,,600 7th Stree SE,,Cedar Rapids,52401,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,400.00,12/20/2013,Cash or cash equivalent,105985713,,,Global Regenerex Tibial Tray Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,9492.50,09/16/2013,Cash or cash equivalent,106033322,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA PAS2,,
Non-covered Recipient Entity,,,,,,,600 7th Stree SE,,Cedar Rapids,52401,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,400.00,08/30/2013,Cash or cash equivalent,105985706,,,Global Regenerex Tibial Tray Study,,
Non-covered Recipient Entity,,,,,,,600 7th Stree SE,,Cedar Rapids,52401,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,200.00,10/18/2013,Cash or cash equivalent,105985717,,,Global Regenerex Tibial Tray Study,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,195.00,08/19/2013,Cash or cash equivalent,106031349,,,ORION,,ORION
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2498.63,12/02/2013,Cash or cash equivalent,106208102,SERETIDE DISKUS,SERETIDE ACCUHALER,A 6 month safety and benefit study of inhaled fluticasone propionate  salmeterol combination versus inhaled fluticasone propionate in the treatment of 6200 pediatric subjects 4 11 years old with persistent asthma,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,275.00,09/16/2013,Cash or cash equivalent,106208106,SERETIDE DISKUS,SERETIDE ACCUHALER,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1276.87,12/18/2013,Cash or cash equivalent,106208104,SERETIDE DISKUS,SERETIDE ACCUHALER,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1500.00,09/16/2013,Cash or cash equivalent,106208105,SERETIDE DISKUS,SERETIDE ACCUHALER,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,207 CROCKER ST,STE 300,DES MOINES,50309-1318,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,1500.00,08/19/2013,Cash or cash equivalent,106032983,,,PLATINUM,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,11207.90,09/13/2013,Cash or cash equivalent,106033320,,,CLINICAL TRIAL FOR THE INGEVITY LEAD,,
Non-covered Recipient Entity,,,,,,,201 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,645.83,09/16/2013,Cash or cash equivalent,105886728,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,201 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,10218.00,08/08/2013,Cash or cash equivalent,105886729,,,ISPR - SNS,,
Non-covered Recipient Entity,,,,,,,201 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,16020.00,11/07/2013,Cash or cash equivalent,105886730,,,ISPR - SNS,,
Non-covered Recipient Entity,,,,,,,600 7th Stree SE,,Cedar Rapids,52401,,,"Biomet, Inc.",100000005643,"Biomet Orthopedics, LLC",IN,300.00,08/30/2013,Cash or cash equivalent,105985705,,,Global Regenerex Tibial Tray Study,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,8207.00,08/08/2013,Cash or cash equivalent,105886725,,,ISPR - SCS,,
Non-covered Recipient Entity,,,,,,,201 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,541.67,09/16/2013,Cash or cash equivalent,105886727,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,4122.00,11/07/2013,Cash or cash equivalent,105886726,,,ISPR - SCS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Shire US Holdings,100000000241,Shire US Holdings,PA,1000.00,10/09/2013,Cash or cash equivalent,105770355,ELAPRASE,,"A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome Mucopolysaccharidosis II",,
Non-covered Recipient Entity,,,,,,,5950 University Ave Ste 321,,West Des Moines,50266,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,1500.00,12/01/2013,Cash or cash equivalent,106163564,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,5950 University Ave Ste 321,,West Des Moines,50266,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,4576.64,08/01/2013,Cash or cash equivalent,106162186,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,PO Box 2758,,Waterloo,50704,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,27970.00,08/07/2013,Cash or cash equivalent,106162748,Afatinib,,LUX-Lung EAP US,,
Non-covered Recipient Entity,,,,,,,1500 Associates Dr,,Dubuque,52002,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,1038.10,12/10/2013,Cash or cash equivalent,106162110,Tiotropium-bromide,,TIOSPIR,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave,,Waterloo,50702,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,1992.50,08/01/2013,Cash or cash equivalent,106161969,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1100.00,09/16/2013,Cash or cash equivalent,106208103,SERETIDE DISKUS,SERETIDE ACCUHALER,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,STE 501,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,11221.96,09/05/2013,Cash or cash equivalent,106203138,AVAMYS,ALLERMIST,HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiovascular disease,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,12003.39,09/04/2013,Cash or cash equivalent,106221369,Gilenya,,CFTY720D2319,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,13458.78,11/12/2013,Cash or cash equivalent,106221370,Gilenya,,CFTY720D2319,,
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2276.10,12/18/2013,Cash or cash equivalent,106123712,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Thoratec Corporation,100000000296,Thoratec Corporation,CA,100.00,08/08/2013,Cash or cash equivalent,106034133,,,SSI STUDY,,
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6825.60,11/22/2013,Cash or cash equivalent,106123583,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1414.00,08/26/2013,Cash or cash equivalent,106110930,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,83.50,08/21/2013,Cash or cash equivalent,106114980,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Covered Recipient Physician,,,33307,JAMES,JOSEPH,POOCK,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702-5047,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.00,11/21/2013,Cash or cash equivalent,106112524,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"Attn- Isam Marar, MD, 1701 West Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1400.00,09/27/2013,Cash or cash equivalent,106123585,Nesina,,Evaluate Cardiovascular Outcomes Following Treatment  with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1281.00,09/03/2013,Cash or cash equivalent,106123587,,,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",,
Non-covered Recipient Entity,,,,,,,"Attn- Isam Marar, MD, 1701 West Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1799.00,08/07/2013,Cash or cash equivalent,106123588,Nesina,,Evaluate Cardiovascular Outcomes Following Treatment  with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2500.00,12/27/2013,Cash or cash equivalent,106123731,,,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,44.16,10/11/2013,Cash or cash equivalent,106126513,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.85,08/16/2013,Cash or cash equivalent,106126375,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,44.16,11/27/2013,Cash or cash equivalent,106126383,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2201 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,190.65,12/12/2013,Cash or cash equivalent,106126142,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Covered Recipient Physician,,,204459,M,IMRAN,DOTANI,1215 DUFF AVE,,AMES,50010-5400,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,35.40,10/30/2013,Cash or cash equivalent,106113559,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"2055 Kimball Ave, Attn Angie Bixby-Ellermann",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5420.70,11/01/2013,Cash or cash equivalent,106119097,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"2055 Kimball Ave, Attn Angie Bixby-Ellermann",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3762.90,11/22/2013,Cash or cash equivalent,106119098,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Covered Recipient Physician,,,5433,ISAM,ELIAS,MARAR,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,35.40,11/21/2013,Cash or cash equivalent,106113517,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Covered Recipient Physician,,,5433,ISAM,ELIAS,MARAR,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,70.80,12/22/2013,Cash or cash equivalent,106113519,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,"1215 Duff Ave, Jeb Lee Administration",,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1330.20,12/12/2013,Cash or cash equivalent,106123543,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,21.90,10/30/2013,Cash or cash equivalent,106111707,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,514.65,09/25/2013,Cash or cash equivalent,106111712,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,187.50,08/26/2013,Cash or cash equivalent,106111715,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Covered Recipient Physician,,,5433,ISAM,ELIAS,MARAR,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,82.60,08/26/2013,Cash or cash equivalent,106113532,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,"McFarland Clinic PC, 1111 Duff Ave",,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,82.80,11/27/2013,Cash or cash equivalent,106126364,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,15.72,11/27/2013,Cash or cash equivalent,106126382,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave.,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,79.24,09/11/2013,Cash or cash equivalent,106126353,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"W Broadway Clinic, 1701 W Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,29.25,09/13/2013,Cash or cash equivalent,106126510,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,Office of Grant Accounting,105 Jessup Hall,Iowa City,64114,,,Amarin Pharma Inc,100000010379,Amarin Pharma Inc.,NJ,22134.00,10/30/2013,Cash or cash equivalent,106215923,Vascepa,,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease  REDUCE-IT  Reduction of Cardiovascular Events with EPA   Intervention Trial",,
Non-covered Recipient Entity,,,,,,,Office of Grant Accounting,105 Jessup Hall,Iowa City,64114,,,Amarin Pharma Inc,100000010379,Amarin Pharma Inc.,NJ,800.00,12/30/2013,Cash or cash equivalent,106216138,Vascepa,,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease  REDUCE-IT  Reduction of Cardiovascular Events with EPA   Intervention Trial",,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,4150.00,12/26/2013,Cash or cash equivalent,106010536,,,CLARITY,,"Complete Lesion Assessment With ffR and IVUS TechnologY CLARITY I. CLARITY I is a pilot study to identify the clinically appropriate endpoints of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia CLI."
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5106.60,11/06/2013,Cash or cash equivalent,106123584,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,396.20,08/07/2013,Cash or cash equivalent,106114094,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,396.20,10/09/2013,Cash or cash equivalent,106114552,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"La Med Ed Found, 2055 Kimball Ave",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,125.25,11/04/2013,Cash or cash equivalent,106114554,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"2055 Kimball Ave, Attn Angie Bixby-Ellermann",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,8307.90,08/23/2013,Cash or cash equivalent,106118975,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"IOWA CITY VA HEALTH CARE SYSTEM, 601 HIGHWAY 6 WEST 151",,IOWA CITY,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5500.00,09/18/2013,Cash or cash equivalent,106122549,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,118.86,08/16/2013,Cash or cash equivalent,106126522,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave.,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,117.76,09/11/2013,Cash or cash equivalent,106126352,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010-5400,,,Dendreon Corporation,100000005479,Dendreon Corporation,WA,2545.00,10/08/2013,Cash or cash equivalent,106180769,PROVENGE,,P10-3,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010-5400,,,Dendreon Corporation,100000005479,Dendreon Corporation,WA,2545.00,10/08/2013,Cash or cash equivalent,106180768,PROVENGE,,P10-3,,
Non-covered Recipient Entity,,,,,,,"1215 Duff Ave, Jeb Lee Administration",,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1342.80,10/17/2013,Cash or cash equivalent,106123555,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"1215 Duff Ave, Jeb Lee Administration",,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,520.20,09/27/2013,Cash or cash equivalent,106123556,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"La Med Ed Found, 2055 Kimball Ave",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,250.50,12/13/2013,Cash or cash equivalent,106114555,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,44.16,08/16/2013,Cash or cash equivalent,106126493,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,15.72,10/11/2013,Cash or cash equivalent,106126499,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,547.20,12/20/2013,Cash or cash equivalent,106123761,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,"W Broadway Clinic, 1701 W Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,100.20,12/13/2013,Cash or cash equivalent,106126136,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.85,11/27/2013,Cash or cash equivalent,106126304,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,118.86,10/11/2013,Cash or cash equivalent,106126514,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave.,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,16.70,08/21/2013,Cash or cash equivalent,106126330,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W. Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,44.16,12/13/2013,Cash or cash equivalent,106126129,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,93.75,09/25/2013,Cash or cash equivalent,106111713,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,"La Med Ed Found, 2055 Kimball Ave",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,22.95,10/31/2013,Cash or cash equivalent,106114553,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.85,10/11/2013,Cash or cash equivalent,106126515,,,"Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control",,
Non-covered Recipient Entity,,,,,,,"W Broadway Clinic, 1701 W Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,22.95,10/22/2013,Cash or cash equivalent,106126518,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,"Attn- Isam Marar, MD, 1701 West Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3200.00,09/27/2013,Cash or cash equivalent,106123586,Nesina,,Evaluate Cardiovascular Outcomes Following Treatment  with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,1701 W. Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,165.60,12/16/2013,Cash or cash equivalent,106126134,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W. Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,15.72,12/13/2013,Cash or cash equivalent,106126152,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,2201 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,9.75,12/30/2013,Cash or cash equivalent,106126174,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,"La Med Ed Found, 2055 Kimball Ave",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,68.85,09/04/2013,Cash or cash equivalent,106114768,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,21.90,12/22/2013,Cash or cash equivalent,106111711,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,15.72,08/16/2013,Cash or cash equivalent,106125326,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,"Attn- Isam Marar, MD, 1701 West Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3156.00,12/09/2013,Cash or cash equivalent,106123692,Nesina,,Evaluate Cardiovascular Outcomes Following Treatment  with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,"Attn- Isam Marar, MD, 1701 West Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,414.00,12/04/2013,Cash or cash equivalent,106123694,Nesina,,Evaluate Cardiovascular Outcomes Following Treatment  with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes,,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,9644.49,08/22/2013,In-kind items and services,106110961,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Covered Recipient Physician,,,117286,TAMARA,L,NELSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,109.50,08/26/2013,Cash or cash equivalent,106111714,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,"2055 Kimball Ave, Attn Angie Bixby-Ellermann",,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1638.90,09/24/2013,Cash or cash equivalent,106119095,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"1215 Duff Ave, Jeb Lee Administration",,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1191.60,08/23/2013,Cash or cash equivalent,106123557,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2201 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,29.25,09/17/2013,Cash or cash equivalent,106126348,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave.,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,158.48,12/02/2013,Cash or cash equivalent,106125773,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,1701 W. Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,118.86,12/13/2013,Cash or cash equivalent,106126491,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,118.86,11/27/2013,Cash or cash equivalent,106126307,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"1701 W Broadway, Attn Jan Patterson",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2005.40,12/20/2013,Cash or cash equivalent,106123730,,,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",,
Non-covered Recipient Entity,,,,,,,1111 Duff Ave.,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,58.88,12/02/2013,Cash or cash equivalent,106126357,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Covered Recipient Teaching Hospital,449,Trinity Medical Center,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2853.84,08/27/2013,In-kind items and services,105929102,BRILINTA,,"A Randomised, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo in Addition to Existing Acetyl Salicylic Acid ASA Therapy in Patients with History of Myocardial Infarction and Risk of Thrombotic Even",,
Covered Recipient Teaching Hospital,449,Trinity Medical Center,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,15840.82,08/26/2013,Cash or cash equivalent,105929513,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Spectrum Pharmaceuticals Inc.,100000011115,Spectrum Pharmaceuticals Inc.,NV,10300.00,08/06/2013,Cash or cash equivalent,106189937,Zevalin,,SPI ZEV 11 301,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,102193.75,09/30/2013,Cash or cash equivalent,105929361,,,AZ Funnel Study,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2260.81,11/04/2013,Cash or cash equivalent,105930762,,,An Observational Study to Assess Respiratory Syncytial Virus RSV-associated Illness in Adults With Chronic Obstructive Pulmonary Disease COPD andor Congestive Heart Failure CHF,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,14015.92,08/29/2013,In-kind items and services,105930693,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,147.20,10/09/2013,Cash or cash equivalent,106114551,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,73.60,12/11/2013,Cash or cash equivalent,106114556,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,316.96,12/11/2013,Cash or cash equivalent,106114563,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Covered Recipient Physician,,,5433,ISAM,ELIAS,MARAR,1701 WEST BOADWAY,,COUNCIL BLUFFS,51501,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.00,12/22/2013,Cash or cash equivalent,106113503,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,"W Broadway Clinic, 1701 W Broadway",,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,178.95,10/23/2013,Cash or cash equivalent,106126517,,,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin",,
Non-covered Recipient Entity,,,,,,,1701 W. Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,79.24,11/04/2013,Cash or cash equivalent,106126520,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,2055 Kimball Ave #101,,Waterloo,50702,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,147.20,08/07/2013,Cash or cash equivalent,106114314,,,"Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events",,
Non-covered Recipient Entity,,,,,,,2201 West Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,98.10,12/13/2013,Cash or cash equivalent,106126135,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Non-covered Recipient Entity,,,,,,,1701 W. Broadway,,Council Bluffs,51501,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.85,12/13/2013,Cash or cash equivalent,106126143,Metformin,,Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia,,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,825.99,08/26/2013,Cash or cash equivalent,106110927,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,170.00,08/02/2013,Cash or cash equivalent,106014719,,,,,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1810.00,10/03/2013,Cash or cash equivalent,106014904,,,,,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2262.00,09/19/2013,Cash or cash equivalent,106014498,,,,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1420.00,10/29/2013,Cash or cash equivalent,106016359,,,,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,3397.50,10/10/2013,Cash or cash equivalent,106016151,,,,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,271.43,09/20/2013,Cash or cash equivalent,106016358,,,,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,3802.50,08/02/2013,Cash or cash equivalent,106016150,,,,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,P.O. BOX 3014,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,1225.00,10/30/2013,Cash or cash equivalent,105927495,Revlimid,,Celgene - CONNECT MM,,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,4388.00,12/10/2013,Cash or cash equivalent,106014499,,,,,
Non-covered Recipient Entity,,,,,,,600 SEVENTH STREET SE,,CEDAR RAPIDS,52401-2112,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,1620.00,09/11/2013,Cash or cash equivalent,105927563,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1800.00,09/10/2013,Cash or cash equivalent,106015735,,,,,
Covered Recipient Teaching Hospital,579,COVENANT MEDICAL CENTER INC,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,3540.00,09/11/2013,Cash or cash equivalent,105927973,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,1351 E. KIMBERLY ROAD,SUITE 100,BETTENDORF,52722,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,575.00,10/30/2013,Cash or cash equivalent,105927120,Revlimid,,Celgene - CONNECT MM,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1394.00,10/24/2013,Cash or cash equivalent,106016559,,,,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,4587.45,10/28/2013,Cash or cash equivalent,105731734,,,,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,390.00,11/22/2013,Cash or cash equivalent,106194528,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,100.00,12/06/2013,Cash or cash equivalent,106194529,,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS 16 TO 80 YEARS OLD WITH PARTIAL ONSET SEIZURES,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,3868.88,09/06/2013,Cash or cash equivalent,106194530,Vimpat,,"A Multicenter, Open-Label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-Onset Seizures",,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DRIVE,,MASON CITY,50401,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,1965.00,11/08/2013,Cash or cash equivalent,106138693,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DRIVE,,MASON CITY,50401,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,275.00,09/10/2013,Cash or cash equivalent,106138574,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DRIVE,,MASON CITY,50401,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,1650.00,08/07/2013,Cash or cash equivalent,106138570,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DRIVE,,MASON CITY,50401,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,900.00,10/07/2013,Cash or cash equivalent,106138583,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2070.00,08/02/2013,Cash or cash equivalent,106015734,,,,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,420.00,10/14/2013,Cash or cash equivalent,106015944,,,,,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,30.00,12/04/2013,Cash or cash equivalent,106014905,,,,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,543.00,11/13/2013,Cash or cash equivalent,106016567,,,,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,667.46,08/23/2013,Cash or cash equivalent,106015102,,,,,
Covered Recipient Teaching Hospital,576,Mercy Medical Center,,,,,701 10th Street SE,,Cedar Rapids,52403,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,40756.80,12/31/2013,In-kind items and services,105768709,ERBITUX,,"A RANDOMIZED, PHASE III STUDY COMPARING CARBOPLATIN-PACLITAXEL ORCARBOPLATIN-PACLITAXEL-BEVACIZUMAB WITH OR WITHOUT CONCURRENT CETUXIMABIN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER -NSCLC-",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,Suite 3262,DES MOINES,50314,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,10209.00,10/24/2013,Cash or cash equivalent,105769777,BYDUREON,,Exenatide Study of Cardiovascular Event Lowering Trial -EXSCEL-- A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Suite 8,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,2250.00,09/27/2013,Cash or cash equivalent,106189311,Humira,,P11-282,,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3730.00,10/16/2013,Cash or cash equivalent,105925541,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,500.00,10/17/2013,Cash or cash equivalent,105887108,,,BLOCK-HF,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,10000.00,10/15/2013,In-kind items and services,105890743,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3955.00,11/14/2013,Cash or cash equivalent,105890129,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2250.00,12/19/2013,Cash or cash equivalent,105890130,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2800.00,12/20/2013,Cash or cash equivalent,105889945,,,Miracle Mid EF,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,10000.00,09/11/2013,In-kind items and services,105890741,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,P.O. BOX 3014,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,1600.00,10/30/2013,Cash or cash equivalent,105927557,Revlimid,,Celgene - Connect CLL,,
Covered Recipient Teaching Hospital,579,COVENANT MEDICAL CENTER INC,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,3000.00,10/30/2013,Cash or cash equivalent,105927936,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST.,,SIOUX CITY,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,4850.00,09/27/2013,Cash or cash equivalent,105928137,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,202 TENTH STREET SE SUITE 285,,CEDAR RAPIDS,52403,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,3350.00,08/21/2013,Cash or cash equivalent,105927957,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,980.00,12/09/2013,Cash or cash equivalent,106015736,,,,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,900.00,10/17/2013,Cash or cash equivalent,105887107,,,BLOCK-HF,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2298.00,10/01/2013,Cash or cash equivalent,105887891,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,27320.00,11/25/2013,Cash or cash equivalent,105887497,,,PainFree SST - Protecta,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3562.00,10/17/2013,Cash or cash equivalent,105890127,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1070.00,10/22/2013,Cash or cash equivalent,105890128,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3780.00,11/13/2013,Cash or cash equivalent,105890149,,,ECG Feedback for CRT,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,601.20,10/11/2013,Cash or cash equivalent,106194527,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Non-covered Recipient Entity,,,,,,,600 7TH STREET SOUTHEAST,,CEDAR RAPIDS,52401,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,6931.80,11/21/2013,Cash or cash equivalent,106194120,Cimzia,,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE FOR INDUCING AND SUSTAINING CLINICAL RESPONSE IN THE TREATMENT OF DMARD-NA?VE ADULTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS PHASE 3?",,
Non-covered Recipient Entity,,,,,,,600 7TH STREET SOUTHEAST,,CEDAR RAPIDS,52401,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,28320.30,08/05/2013,Cash or cash equivalent,106194119,Cimzia,,A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE FOR INDUCING AND SUSTAINING CLINICAL RESPONSE IN THE TREATMENT OF DMARD NA VE ADULTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS PHASE 3,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,195.00,08/09/2013,Cash or cash equivalent,106194526,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (?16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES",,
Non-covered Recipient Entity,,,,,,,1301 PENNSYLVANIA AVE STE 411,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,650.00,10/09/2013,Cash or cash equivalent,105925542,,,OPTIMUM  LEAD REGISTRY,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6TH AVE,,DES MOINES,50314,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,4280.00,10/09/2013,Cash or cash equivalent,105925127,,,SCORE,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,323.00,12/31/2013,In-kind items and services,105931361,,,Surveillance of Ceftazidime avibactam Activity Tested Against Clinical Isolates in Europe - 2011,,
Covered Recipient Teaching Hospital,569,St Lukes Methodist Hospital,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,650.00,10/16/2013,Cash or cash equivalent,105926356,,,QUADRIPOLAR PACING PAS,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,323.00,12/31/2013,In-kind items and services,105931360,,,Contemporary 2009-2011 Antibiogram Analysis for HABP and VABP Pathogens From Europe Plus Mediterranean Region and China and USA,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,323.00,12/31/2013,In-kind items and services,105931362,,,Surveillance of Ceftazidime-Avibactam Activity Tested Against Isolates in the United States 2011 - USA Surveillance 2011,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6TH AVE,,DES MOINES,50314,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,450.00,10/16/2013,Cash or cash equivalent,105924963,,,QuickFlex 258T PAS,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,24644.62,08/26/2013,Cash or cash equivalent,105929381,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4950.00,10/16/2013,Cash or cash equivalent,106177375,,,,,
Covered Recipient Physician,,,156426,ERIC,A,BARP,5950 UNIVERSITY AVE,STE 160,WEST DES MOINES,50266-8216,Medical Doctor,Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,17.90,10/19/2013,In-kind items and services,106220323,,,,,
Covered Recipient Physician,,,209220,MARK,,MORISHIGE,2800 PIERCE ST,SUITE #101,SIOUX CITY,51104-3755,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,120.03,10/19/2013,Cash or cash equivalent,106220325,,,,,
Covered Recipient Physician,,,226425,Brian,D.,Adams,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Hand Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,371.85,09/27/2013,Cash or cash equivalent,106220329,,,,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,12/02/2013,In-kind items and services,106144178,,,Rheos Pivotal Trial,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,08/30/2013,In-kind items and services,106144186,,,Rheos Pivotal Trial,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,4364.06,09/05/2013,Cash or cash equivalent,106200097,SELZENTRY,,A MULTICENTER RANDOMIZED DOUBLE BLIND COMPARATIVE TRIAL OF MARAVIROC and DARUNAVIRRITONAVIR VERSUS EMTRICITABINETENOFOVIR and DARUNAVIRRITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NA VE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,121.44,09/20/2013,Cash or cash equivalent,106200366,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,656.44,08/22/2013,Cash or cash equivalent,106200575,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,11/18/2013,In-kind items and services,106144164,,,Rheos Pivotal Trial,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,4686.74,10/25/2013,Cash or cash equivalent,106144153,,,Rheos Pivotal Trial,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1175.62,12/11/2013,Cash or cash equivalent,106200187,SELZENTRY,,A MULTICENTER RANDOMIZED BLINDED PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY OF MARAVIROC IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN HIV1INFECTED SUBJECTS COINFECTED WITH HEPATITIS C ANDOR HEPATITIS B VIRUS,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,08/20/2013,In-kind items and services,106144135,,,Rheos Pivotal Trial,,
Covered Recipient Physician,,,209220,MARK,,MORISHIGE,2800 PIERCE ST,SUITE #101,SIOUX CITY,51104-3755,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,13.46,12/04/2013,Cash or cash equivalent,106220326,,,,,
Covered Recipient Physician,,,209220,MARK,,MORISHIGE,2800 PIERCE ST,SUITE #101,SIOUX CITY,51104-3755,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,65.21,12/04/2013,Cash or cash equivalent,106220328,,,,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"EMD Serono, Inc.",100000000127,"EMD Serono, Inc.",MA,7000.00,12/05/2013,Cash or cash equivalent,106192097,Egrifta,,EGRIFTA DIABETIC RETINOPATHY STUDY,,112917
Covered Recipient Physician,,,209220,MARK,,MORISHIGE,2800 PIERCE ST,SUITE #101,SIOUX CITY,51104-3755,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,26.33,10/18/2013,Cash or cash equivalent,106220324,,,,,
Covered Recipient Physician,,,1189224,Daniel,,Fabiano,600 7TH ST SE,,CEDAR RAPIDS,52401-2112,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Sports Medicine,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,371.85,09/27/2013,Cash or cash equivalent,106220331,,,,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"ARIAD Pharmaceuticals, Inc.",100000010550,"ARIAD Pharmaceuticals, Inc.",MA,6000.00,09/03/2013,Cash or cash equivalent,106210984,Iclusig,,EPIC,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242,,,"ARIAD Pharmaceuticals, Inc.",100000010550,"ARIAD Pharmaceuticals, Inc.",MA,12235.00,10/01/2013,Cash or cash equivalent,106210985,Iclusig,,EPIC,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,49.17,09/20/2013,Cash or cash equivalent,106200521,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,2137.50,08/02/2013,Cash or cash equivalent,106200111,SELZENTRY,,A MULTICENTER RANDOMIZED DOUBLE BLIND COMPARATIVE TRIAL OF MARAVIROC and DARUNAVIRRITONAVIR VERSUS EMTRICITABINETENOFOVIR and DARUNAVIRRITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NA VE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,60.50,09/20/2013,Cash or cash equivalent,106200705,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,50.95,09/20/2013,Cash or cash equivalent,106200723,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,209220,MARK,,MORISHIGE,2800 PIERCE ST,SUITE #101,SIOUX CITY,51104-3755,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,18.16,12/04/2013,Cash or cash equivalent,106220327,,,,,
Covered Recipient Physician,,,226425,Brian,D.,Adams,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Hand Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,579.68,09/27/2013,Cash or cash equivalent,106220330,,,,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,58.41,09/20/2013,Cash or cash equivalent,106200539,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,94.43,09/20/2013,Cash or cash equivalent,106200690,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,31.00,09/20/2013,Cash or cash equivalent,106200363,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,10440.00,10/25/2013,Cash or cash equivalent,106144152,,,Rheos Pivotal Trial,,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,STE 501,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,6131.02,12/19/2013,Cash or cash equivalent,106203139,AVAMYS,ALLERMIST,HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiovascular disease,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,08/30/2013,In-kind items and services,106144137,,,Rheos Pivotal Trial,,
Non-covered Recipient Entity,,,,,,,5500 Lakeview Parkway,,Davenport,52807,,,"Roche Molecular Systems, Inc.",100000005630,"Roche Molecular Systems, Inc.",CA,24300.00,08/01/2013,Cash or cash equivalent,106193536,,,MRSA/SA/Cdiff,,
Covered Recipient Teaching Hospital,582,State University of Iowa,,,,,200 HAWKINS DRIVE,,Iowa City,52242,,,"Roche Molecular Systems, Inc.",100000005630,"Roche Molecular Systems, Inc.",CA,1300.00,11/26/2013,Cash or cash equivalent,106193537,,,CMV,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,34.98,09/20/2013,Cash or cash equivalent,106200501,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,10/08/2013,In-kind items and services,106144145,,,Rheos Pivotal Trial,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50314,,,"CVRx, Inc.",100000010805,"CVRx, Inc.",MN,26000.00,11/01/2013,In-kind items and services,106144159,,,Rheos Pivotal Trial,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,279.06,09/20/2013,Cash or cash equivalent,106200549,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,91.67,09/20/2013,Cash or cash equivalent,106200553,TRELAVUE,,A Phase IIIb randomized openlabel study of the safety and efficacy of dolutegravirabacavirlamivudine once daily compared to atazanavir and ritonavir plus tenofoviremtricitabine once daily in HIV1 infected antiretroviral therapy naive women,,
Non-covered Recipient Entity,,,,,,,5901 WESTOWN PKWY,STE 250,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,6080.00,11/15/2013,Cash or cash equivalent,105940305,,,Breast Implant Follow-up Studies,,
Non-covered Recipient Entity,,,,,,,3705 RIVER RIDGE DR NE,,CEDAR RAPIDS,52402,,,Allergan Inc.,100000000278,Allergan Inc.,CA,140.00,11/15/2013,Cash or cash equivalent,105940150,,,Breast Implant Follow-up Studies,,
Non-covered Recipient Entity,,,,,,,1100 6TH ST,STE 202,CORALVILLE,52241,,,Allergan Inc.,100000000278,Allergan Inc.,CA,460.00,11/15/2013,Cash or cash equivalent,105939956,,,Breast Implant Follow-up Studies,,
Non-covered Recipient Entity,,,,,,,4334 E 53RD ST,,DAVENPORT,52807,,,Allergan Inc.,100000000278,Allergan Inc.,CA,100.00,11/15/2013,Cash or cash equivalent,105940095,,,Breast Implant Follow-up Studies,,
Non-covered Recipient Entity,,,,,,,2000 GRAND AVE,,DES MOINES,50312,,,Allergan Inc.,100000000278,Allergan Inc.,CA,1160.00,11/15/2013,Cash or cash equivalent,105941123,,,Breast Implant Follow-up Studies,,
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1300.00,10/09/2013,Cash or cash equivalent,106217583,,,Clinical Study of the Nucleus Hybrid Cochlear Implant Hybrid L24,,Institutional Review Board payment
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,673.00,10/09/2013,Cash or cash equivalent,106217587,,,Implantation of the Cochlear Nucleus System in Adults with Single Sided Deafness,,Research fees
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,,CLIVE,50325,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,3400.00,10/25/2013,Cash or cash equivalent,106197949,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,202 10TH ST,,CEDAR RAPIDS,52403,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,5573.00,11/11/2013,Cash or cash equivalent,106197736,,,"A phase 2 Multicenter, open-label, follow up study to assess the long term safety and efficacy of CDP6038 administered subcutaneously to subjects with active rheumatoid arthritis who completed study RA0056.",,
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1300.00,12/09/2013,Cash or cash equivalent,106217586,,,Implantation of the Cochlear Nucleus System in Adults with Single Sided Deafness,,Institutional Review Board payment
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,558.00,12/31/2013,In-kind items and services,105735114,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,http://clinicaltrials.gov/ct2/show/NCT01602224,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,170754.24,08/13/2013,Cash or cash equivalent,105737156,,,A COMPARISON OF LY2605541 ONCE DAILY AT A FIXED TIME WITH LY2605541 VARIABLE TIME OF DOSING IN PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS - AN OPEN LABEL RANDOMIZED CROSSOVER STUDY,http://clinicaltrials.gov/ct2/show/NCT01792284,
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,220.00,11/11/2013,Cash or cash equivalent,106217585,,,Clinical Study of the Nucleus Hybrid Cochlear Implant Hybrid L24,,Research fees
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,618.00,11/11/2013,Cash or cash equivalent,106217588,,,Implantation of the Cochlear Nucleus System in Adults with Single Sided Deafness,,Research fees
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1300.00,12/02/2013,Cash or cash equivalent,106217589,,,Evaluation of the Nucleus Hybrid L24 Cochlear Implant System IDE Supplement Investigation of Nucleus 6 Sound Processor Signal Processing Algorithms,,Institutional Review Board payment
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,275.00,12/02/2013,Cash or cash equivalent,106217690,,,Evaluation of A Revised Indication for Determining Adult Cochlear Implant Candidacy,,Research fees
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Siemens Hearing Instruments, Inc.",100000010601,"Siemens Hearing Instruments, Inc.",NJ,33957.00,10/30/2013,Cash or cash equivalent,106219719,,,Systematically Investigating the Effect of Directional Speech Enhancement on Listening Effort,,"In the proposed study, the effect of the DSE on listening effort, which is the cognitive resource allocated for speech recognition, will be systematically examined using an optimized dual-task paradig"
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,500.00,11/25/2013,Cash or cash equivalent,105737509,,,A PROSPECTIVE RANDOMIZED OPEN LABEL COMPARISON OF A LONG ACTING BASAL INSULIN ANALOG LY2963016 TO LANTUS IN COMBINATION WITH MEALTIME INSULIN LISPRO IN ADULT PATIENTS WITH TYPE 1 DIABETES MELLITUS,http://clinicaltrials.gov/ct2/show/NCT01421147,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,33591.00,10/02/2013,Cash or cash equivalent,105736520,,,ASSESSMENT OF CLINICAL EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION WITH EVACETRAPIB IN PATIENTS AT A HIGH RISK FOR VASCULAR OUTCOMES,http://clinicaltrials.gov/ct2/show/NCT01687998,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2126.00,08/06/2013,Cash or cash equivalent,105736940,,,THE IMPACT OF LY2605541 VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS ADVANCED TO MULTIPLE INJECTION BOLUS INSULIN WITH INSULIN LISPRO - A DOUBLE BLIND RANDOMIZED 26-WEEK STUDY - THE IMAGINE 4 STUDY,http://clinicaltrials.gov/ct2/show/NCT01468987,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,500.00,11/25/2013,Cash or cash equivalent,105737514,,,A PROSPECTIVE RANDOMIZED DOUBLE BLIND COMPARISON OF A LONG ACTING BASAL INSULIN ANALOG LY2963016 TO LANTUS IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS - THE ELEMENT 2 STUDY,http://clinicaltrials.gov/ct2/show/NCT01421459,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,67173.80,09/16/2013,Cash or cash equivalent,105738989,AXIRON,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL STUDY WITH AN OPEN LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE SEX DRIVE AND ENERGY IN HYPOGONADAL MEN,http://clinicaltrials.gov/ct2/show/NCT01816295,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,18841.00,08/06/2013,Cash or cash equivalent,105736938,,,A COMPARISON OF LY2605541 VERSUS HUMAN INSULIN NPH AS BASAL INSULIN TREATMENT IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS NOT ADEQUATELY CONTROLLED WITH 2 OR MORE ORAL ANTIHYPERGLYCEMIC MEDICATIONS - AN OPEN LABEL RANDOMIZED STUDY,http://clinicaltrials.gov/ct2/show/NCT01790438,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,5735.00,12/31/2013,In-kind items and services,105736939,,,A COMPARISON OF LY2605541 VERSUS HUMAN INSULIN NPH AS BASAL INSULIN TREATMENT IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS NOT ADEQUATELY CONTROLLED WITH 2 OR MORE ORAL ANTIHYPERGLYCEMIC MEDICATIONS - AN OPEN LABEL RANDOMIZED STUDY,http://clinicaltrials.gov/ct2/show/NCT01790438,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,4TH FL,CEDAR RAPIDS,52401,,,Stryker Corporation,100000010503,Stryker Corporation,MI,90.00,10/01/2013,Cash or cash equivalent,106166927,,,Triathlon Cruciate Retaining CR Total Knee System Outcomes Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,161.00,08/27/2013,Cash or cash equivalent,105730547,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount reported represents a compilation of the payments or other transfers of value, including, but not limited to, study drug, service costs, supplies, equipment and rentals, provided by Incyte Corporation or by a third party vendor on behalf of Incyte Corporation for the data collection period."
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD ST,,DAVENPORT,52803-2448,,,The Medicines Company,100000010428,The Medicines Company,NJ,4000.00,10/23/2013,Cash or cash equivalent,106219112,ANGIOMAX,,ENDOMAX MDCO-BIV-12-03,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4713.05,08/01/2013,Cash or cash equivalent,105730546,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount reported represents a compilation of the payments or other transfers of value, including, but not limited to, study drug, service costs, supplies, equipment and rentals, provided by Incyte Corporation or by a third party vendor on behalf of Incyte Corporation for the data collection period."
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5888.44,10/30/2013,Cash or cash equivalent,105730549,,,"An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis",,"The amount reported represents a compilation of the payments or other transfers of value, including, but not limited to, study drug, service costs, supplies, equipment and rentals, provided by Incyte Corporation or by a third party vendor on behalf of Incyte Corporation for the data collection period."
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,52.00,11/13/2013,Cash or cash equivalent,105730550,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount reported represents a compilation of the payments or other transfers of value, including, but not limited to, study drug, service costs, supplies, equipment and rentals, provided by Incyte Corporation or by a third party vendor on behalf of Incyte Corporation for the data collection period."
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10160.55,10/07/2013,Cash or cash equivalent,105730548,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount reported represents a compilation of the payments or other transfers of value, including, but not limited to, study drug, service costs, supplies, equipment and rentals, provided by Incyte Corporation or by a third party vendor on behalf of Incyte Corporation for the data collection period."
Non-covered Recipient Entity,,,,,,,450 Laurel St Ste A,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,500.00,10/24/2013,Cash or cash equivalent,105933755,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,8760.00,08/06/2013,Cash or cash equivalent,106018559,,,Video laryngoscope comparison,,
Covered Recipient Physician,,,42003,JASON,JONATHAN,JONES,4405 HAMILTON BLVD,,SIOUX CITY,51104-1140,Medical Doctor,Allopathic & Osteopathic Physicians|Ophthalmology,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,1572.50,11/14/2013,In-kind items and services,106005099,,,Comparison of Visual Acuity With Multifocal 2.5 D Intraocular Lenses IOLs and Monofocal IOLs,,
Non-covered Recipient Entity,,,,,,,1111 Sixth Avenue,West Building Suite 400,Des Moines,50314,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,19998.09,10/28/2013,Cash or cash equivalent,106216989,Gilenya,,CFTY720D2312,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,4629.06,08/19/2013,In-kind items and services,106200127,SELZENTRY,,A multicenter randomized double blinded comparative trial of Maraviroc Darunavir Ritonavir vs Emtricitabine Tenofovir Darunavir Ritonavir for the treatment of antiretroviral naive HIV infected patients with Ccr5 Tropic HIV 1,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,11572.65,10/03/2013,In-kind items and services,106200128,SELZENTRY,,A multicenter randomized double blinded comparative trial of Maraviroc Darunavir Ritonavir vs Emtricitabine Tenofovir Darunavir Ritonavir for the treatment of antiretroviral naive HIV infected patients with Ccr5 Tropic HIV 1,,
Non-covered Recipient Entity,,,,,,,DBAJONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,658.00,10/31/2013,Cash or cash equivalent,105999780,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens IOL,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,19634.04,08/19/2013,In-kind items and services,106200129,SELZENTRY,,A multicenter randomized double blinded comparative trial of Maraviroc Darunavir Ritonavir vs Emtricitabine Tenofovir Darunavir Ritonavir for the treatment of antiretroviral naive HIV infected patients with Ccr5 Tropic HIV 1,,
Non-covered Recipient Entity,,,,,,,DBAJONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,7200.00,12/12/2013,Cash or cash equivalent,105999781,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens IOL,,
Non-covered Recipient Entity,,,,,,,DBAJONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,658.00,09/12/2013,Cash or cash equivalent,105999777,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens IOL,,
Non-covered Recipient Entity,,,,,,,1111 Sixth Avenue,West Building Suite 400,Des Moines,50314,,,Novartis Pharma AG,100000000058,Novartis Pharma AG,,60.00,11/25/2013,In-kind items and services,106216988,Gilenya,,CFTY720D2312,,
Non-covered Recipient Entity,,,,,,,DBAJONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,658.00,08/01/2013,Cash or cash equivalent,105999782,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens IOL,,
Non-covered Recipient Entity,,,,,,,DBAJONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,658.00,10/03/2013,Cash or cash equivalent,105999778,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens IOL,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Musculoskeletal Transplant Foundation Inc.,100000000081,Musculoskeletal Transplant Foundation Inc.,NJ,30000.00,10/17/2013,Cash or cash equivalent,105730497,,,,,
Non-covered Recipient Entity,,,,,,,DBAJONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,658.00,09/26/2013,Cash or cash equivalent,105999779,,,Post Approval Study of the AcrySof IQ Toric High Cylinder Power Intraocular Lens IOL,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,15500.00,09/06/2013,Cash or cash equivalent,106217901,,,,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,49085.10,10/03/2013,In-kind items and services,106200126,SELZENTRY,,A multicenter randomized double blinded comparative trial of Maraviroc Darunavir Ritonavir vs Emtricitabine Tenofovir Darunavir Ritonavir for the treatment of antiretroviral naive HIV infected patients with Ccr5 Tropic HIV 1,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2000.00,09/06/2013,Cash or cash equivalent,106217902,,,,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,1215 DUFF AVE,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1210.50,08/20/2013,Cash or cash equivalent,106202118,ARZERRA,,Phase III Randomized Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab Containing Therapy,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 Pleasant St,,Des Moines,50309,,,Covidien LP,100000000083,Covidien LP,MA,4150.00,10/30/2013,Cash or cash equivalent,106103709,CVI,,ILLUMENATE Pivotal,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,Covidien LP,100000000083,Covidien LP,MA,36.24,11/06/2013,Cash or cash equivalent,106103748,,,DURABILITY ILIAC,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010-3014,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,4849.25,11/13/2013,Cash or cash equivalent,106142384,COMETRIQ,,A Phase 3. Randomized. Double-blind. Controlled Study of Cabozantinib -XL184- vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,Covidien LP,100000000083,Covidien LP,MA,50.00,11/06/2013,Cash or cash equivalent,106103168,,,DURABILITY ILIAC,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,Covidien LP,100000000083,Covidien LP,MA,50.00,10/23/2013,Cash or cash equivalent,106102923,,,DURABILITY ILIAC,,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010-3014,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,5000.00,08/15/2013,Cash or cash equivalent,106142385,COMETRIQ,,A Phase 3. Randomized. Double-blind. Controlled Study of Cabozantinib -XL184- vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,1215 Pleasant St,Suite 618,Des Moines,50309,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,Covidien LP,100000000083,Covidien LP,MA,433.33,11/13/2013,Cash or cash equivalent,106103291,CVI,,ILLUMENATE Pivotal,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,11640.75,08/15/2013,Cash or cash equivalent,106142586,COMETRIQ,,A Phase 3. Randomized. Double-blind. Controlled Study of Cabozantinib -XL184- vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,3980.13,11/13/2013,Cash or cash equivalent,106142587,COMETRIQ,,A Phase 3. Randomized. Double-blind. Controlled Study of Cabozantinib -XL184- vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,1300.00,10/02/2013,Cash or cash equivalent,106142767,COMETRIQ,,A Phase 3. randomized. double-blind. controlled trial of cabozantinib -XL184- vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer,,
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Covidien LP,100000000083,Covidien LP,MA,1985.00,10/30/2013,Cash or cash equivalent,106103747,,,VISIBILITY ILIAC,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,390.00,12/04/2013,Cash or cash equivalent,106142768,COMETRIQ,,A Phase 3. randomized. double-blind. controlled trial of cabozantinib -XL184- vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer,,
Non-covered Recipient Entity,,,,,,,5880 University Ave #208,,West Des Moines,50266,,,Covidien LP,100000000083,Covidien LP,MA,400.00,10/30/2013,Cash or cash equivalent,106103771,,,CREATE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,3487.50,10/25/2013,Cash or cash equivalent,106007161,,,"A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727 SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins",,"This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study of alirocumab REGN727 SAR236553 in patients with primary hypercholesterolemia and moderate, high, or very high CV risk, who are intolerant to statins."
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,500.00,09/11/2013,Cash or cash equivalent,106142585,COMETRIQ,,A Phase 3. Randomized. Double-blind. Controlled Study of Cabozantinib -XL184- vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,3011.00,11/20/2013,Cash or cash equivalent,105885121,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,12250.23,12/31/2013,In-kind items and services,105737155,,,A COMPARISON OF LY2605541 ONCE DAILY AT A FIXED TIME WITH LY2605541 VARIABLE TIME OF DOSING IN PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS - AN OPEN LABEL RANDOMIZED CROSSOVER STUDY,http://clinicaltrials.gov/ct2/show/NCT01792284,
Covered Recipient Teaching Hospital,569,ST LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,310.08,10/07/2013,Cash or cash equivalent,105731733,,,A PHASE 4 RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SUPERIORITY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE -TDF- IN COMBINATION WITH PEGINTERFERON A-2A -PEGASYS- VERSUS STANDARD OF CARE TENOFOVIR DISOPROXIL FUMARATE MONOTHERAPY OR PEGINTERFERON A-2A MONOTHERAPY FOR 48 WEEKS IN NON CIRRHOTIC SUBJECTS WITH HBEAG POSITIVE OR HBEAG NEGATIVE CHRONIC HEPATITIS B - CHB,http://clinicaltrials.gov/ct2/show/NCT01277601,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 341,,WEST DES MOINES,50266,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,7903.00,08/06/2013,Cash or cash equivalent,105736719,,,A COMPARISON OF LY2605541 VERSUS INSULIN GLARGINE AS BASAL INSULIN TREATMENT IN COMBINATION WITH ORAL ANTI HYPERGLYCEMIA MEDICATIONS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS - A DOUBLE BLIND RANDOMIZED STUDY,http://clinicaltrials.gov/ct2/show/NCT01435616,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1347.00,09/12/2013,Cash or cash equivalent,105885119,,,PSR,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,6249.00,08/13/2013,Cash or cash equivalent,105737090,,,THE IMPACT OF LY2605541 VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH PREPRANDIAL INSULIN LISPRO - A DOUBLE BLIND RANDOMIZED 52 WEEK STUDY,http://clinicaltrials.gov/ct2/show/NCT01454284,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,339.81,08/02/2013,In-kind items and services,105736519,,,ASSESSMENT OF CLINICAL EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION WITH EVACETRAPIB IN PATIENTS AT A HIGH RISK FOR VASCULAR OUTCOMES,http://clinicaltrials.gov/ct2/show/NCT01687998,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,560.70,12/19/2013,In-kind items and services,105731735,,,A RANDOMIZED OPEN LABEL PHASE 2 STUDY EVALUATING LY2875358 PLUS ERLOTINIB AND LY2875358 MONOTHERAPY IN MET DIAGNOSTIC POSITIVE NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO ERLOTINIB,http://clinicaltrials.gov/ct2/show/NCT01900652,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,4743.00,09/25/2013,Cash or cash equivalent,105885120,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,7792.00,12/31/2013,In-kind items and services,105738988,AXIRON,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL STUDY WITH AN OPEN LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE SEX DRIVE AND ENERGY IN HYPOGONADAL MEN,http://clinicaltrials.gov/ct2/show/NCT01816295,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 341,,WEST DES MOINES,50266,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,45.00,12/31/2013,In-kind items and services,105736720,,,A COMPARISON OF LY2605541 VERSUS INSULIN GLARGINE AS BASAL INSULIN TREATMENT IN COMBINATION WITH ORAL ANTI HYPERGLYCEMIA MEDICATIONS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS - A DOUBLE BLIND RANDOMIZED STUDY,http://clinicaltrials.gov/ct2/show/NCT01435616,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Thoratec Corporation,100000000296,Thoratec Corporation,CA,2176.50,11/26/2013,Cash or cash equivalent,106034155,,,SSI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,856.00,10/08/2013,Cash or cash equivalent,152358114,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1306.00,10/08/2013,Cash or cash equivalent,152348176,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1238.00,10/08/2013,Cash or cash equivalent,152358338,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1050.00,10/08/2013,Cash or cash equivalent,152358972,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1238.00,10/08/2013,Cash or cash equivalent,152347156,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1050.00,10/08/2013,Cash or cash equivalent,152343666,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1425.00,10/08/2013,Cash or cash equivalent,152343416,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1050.00,10/08/2013,Cash or cash equivalent,152343426,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,856.00,10/08/2013,Cash or cash equivalent,152359124,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,931.00,10/08/2013,Cash or cash equivalent,152343418,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1425.00,10/08/2013,Cash or cash equivalent,152358612,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,495.00,11/28/2013,Cash or cash equivalent,23294685,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1350.00,10/08/2013,Cash or cash equivalent,152347490,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,850.00,10/08/2013,Cash or cash equivalent,152343668,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,856.00,10/08/2013,Cash or cash equivalent,152343420,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,856.00,10/08/2013,Cash or cash equivalent,152343422,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,856.00,10/08/2013,Cash or cash equivalent,152343424,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1044.25,10/08/2013,Cash or cash equivalent,152355716,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1044.25,10/08/2013,Cash or cash equivalent,152348174,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,856.00,10/08/2013,Cash or cash equivalent,152355280,Halaven,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,615.00,11/04/2013,Cash or cash equivalent,23294684,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,1 Edmundson Pl,Ste 500,Council Bluffs,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,5150.00,12/16/2013,Cash or cash equivalent,12055124,,,Outcomes of Hip Arthroplasty Using A DePuy Total Hip System and Outcomes of Knee Arthroplasty Using a DePuy Knee System,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6Th Ave,,Des Moines,50314-2610,,,"Medical Engineering and Development Institute, Inc.",100000005386,"Medical Engineering and Development Institute, Inc.",IN,112.00,10/10/2013,Cash or cash equivalent,28263738,,,Zenith TX2 TAA Endovascular Graft Post-Approval Study,,"Clinical trials provide real world data on the efficacy of products and procedures. Payments are made directly to clinical study sites that are providing patient care. These payments cover costs of start-up, data and imaging collection, institutional overhead and administrative fees, and non-standard of care tests, imaging, and procedures. Payments to vendors that provide support services for research, such as core labs, e.g., imaging monitoring, are also included here."
Non-covered Recipient Entity,,,,,,,1 Edmundson Pl,Ste 500,Council Bluffs,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,900.00,09/18/2013,Cash or cash equivalent,12055122,,,Outcomes Tracking   Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,3000.00,10/24/2013,Cash or cash equivalent,12055198,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,1 Edmundson Pl,Ste 500,Council Bluffs,51503-4619,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,9375.00,10/21/2013,Cash or cash equivalent,12055123,,,Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,100397.57,10/01/2013,Cash or cash equivalent,4238420,,,"Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes",,"The amount reported represents a compilation of the payments or other transfers of value, including, but not limited to, study drug, service costs, supplies, equipment and rentals, provided by Incyte Corporation or by a third party vendor on behalf of Incyte Corporation for the data collection period."
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,375.00,10/07/2013,Cash or cash equivalent,23294683,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803,,,"Cardica, Inc.",100000005621,"Cardica, Inc.",CA,3922.50,09/26/2013,Cash or cash equivalent,106105153,,,MAGIC,,
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803,,,"Cardica, Inc.",100000005621,"Cardica, Inc.",CA,1000.00,11/07/2013,Cash or cash equivalent,106105161,,,MAGIC,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,35.80,08/16/2013,In-kind items and services,25962105,,,Alisertib  MLN8237  or Investigator's Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1150.00,09/19/2013,Cash or cash equivalent,25955719,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,5000.00,12/10/2013,Cash or cash equivalent,25964240,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,44.75,10/22/2013,In-kind items and services,25963381,,,Alisertib  MLN8237  or Investigator's Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,112.80,12/19/2013,In-kind items and services,25955629,,,Alisertib  MLN8237  or Investigator's Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1762.50,09/19/2013,Cash or cash equivalent,25957300,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,5125.00,09/19/2013,Cash or cash equivalent,25964302,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1062.50,09/19/2013,Cash or cash equivalent,25955375,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biosense Webster, Inc.",100000005693,"Biosense Webster, Inc.",CA,2062.50,08/06/2013,In-kind items and services,11170663,,,"NAVISTAR THERMOCOOL SF Catheter  Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population",,
Non-covered Recipient Entity,,,,,,,701 10th St Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2057.22,10/29/2013,Cash or cash equivalent,105886135,,,PRESTIGE LP,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,2968.14,09/09/2013,Cash or cash equivalent,25960790,VELCADE,,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,25011.16,09/18/2013,Cash or cash equivalent,25960327,,,Alisertib  MLN8237  or Investigator's Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,3750.00,09/19/2013,Cash or cash equivalent,25962367,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT STE 8,,CLIVE,50325,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,4097.00,09/10/2013,Cash or cash equivalent,25963186,,,Study of Vedolizumab  MLN0002  in Patients With Moderate to Severe Crohn's Disease,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,500.00,12/10/2013,Cash or cash equivalent,25964190,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,7050.00,12/11/2013,Cash or cash equivalent,25965703,VELCADE,,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,8.95,11/15/2013,In-kind items and services,25966193,,,Alisertib  MLN8237  or Investigator's Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,2500.00,10/16/2013,Cash or cash equivalent,25960325,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,140.65,12/11/2013,Cash or cash equivalent,25956475,VELCADE,,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,37.65,09/24/2013,In-kind items and services,25962328,,,Alisertib  MLN8237  or Investigator's Choice in Patients With Relapsed Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1000.00,09/19/2013,Cash or cash equivalent,25955196,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/16/2013,Cash or cash equivalent,29767345,Non-Covered Product,,METMAB PHIII NSCLC,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2580.20,11/12/2013,Cash or cash equivalent,29771063,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,Cordis Corporation,100000005411,Cordis Corporation,CA,2400.00,08/14/2013,In-kind items and services,10455605,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3570.78,10/02/2013,Cash or cash equivalent,29763937,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,500.00,08/14/2013,In-kind items and services,10455538,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,50309,,,Cordis Corporation,100000005411,Cordis Corporation,CA,22400.00,08/02/2013,In-kind items and services,10455872,,,INSPIRATION,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4000.00,11/08/2013,In-kind items and services,10455662,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,2145.75,09/13/2013,Cash or cash equivalent,107135862,,,CT002 MarrowStim PAD Kit,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,18791.25,09/13/2013,Cash or cash equivalent,107135868,,,CT002 MarrowStim PAD Kit,,
Covered Recipient Physician,,,1045610,KATHRYN,E,GILLIGAN,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,12/30/2013,Cash or cash equivalent,29766256,Non-Covered Product,,MOSAIC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1068.19,11/12/2013,Cash or cash equivalent,29771020,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,Cordis Corporation,100000005411,Cordis Corporation,CA,3900.00,10/15/2013,In-kind items and services,10455723,,,ELITE,,
Non-covered Recipient Entity,,,,,,,4150 KIMBALL AVE,,WATERLOO,50701,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,17952.94,11/08/2013,Cash or cash equivalent,29760515,Avastin,,AVASTIN AS ADJUVANT TREATMENT IN BC PATIENTS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6526.00,10/23/2013,Cash or cash equivalent,29773684,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,50309,,,Cordis Corporation,100000005411,Cordis Corporation,CA,5800.00,08/14/2013,In-kind items and services,10455594,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biomet, Inc.",100000005640,"Biomet Biologics, LLC",IN,12348.75,08/02/2013,Cash or cash equivalent,107135874,,,BBIO.CR.CT002 Marrowstim Pad Kit,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,8809.75,08/22/2013,Cash or cash equivalent,29775171,Perjeta,,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB&PERTUZUMAB,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/16/2013,Cash or cash equivalent,29767568,Non-Covered Product,,METMAB PHIII NSCLC,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1401.75,10/30/2013,Cash or cash equivalent,29771816,Non-Covered Product,,SFTY & EFFC OF MPSK3169A IN PTS WTH CORON HRT DIS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,18569.32,09/04/2013,Cash or cash equivalent,29763434,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3020.00,10/09/2013,Cash or cash equivalent,29764264,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,166.00,09/23/2013,Cash or cash equivalent,29773034,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492747,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1133.10,10/10/2013,Cash or cash equivalent,29759221,Zelboraf,,ZELBORAF ROLLOVER STUDY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,781.60,09/20/2013,Cash or cash equivalent,29772947,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1585.80,09/11/2013,Cash or cash equivalent,29767663,Non-Covered Product,,12-WEEK EFFICACY STUDY IN FXS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2117.26,08/07/2013,Cash or cash equivalent,29767806,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492723,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492735,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492728,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492727,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/16/2013,Cash or cash equivalent,29767343,Non-Covered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6497.85,09/05/2013,Cash or cash equivalent,29766446,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,904.95,08/02/2013,Cash or cash equivalent,29768444,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,50309,,,Cordis Corporation,100000005411,Cordis Corporation,CA,250.00,10/30/2013,In-kind items and services,10455533,,,STROLL,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,09/23/2013,Cash or cash equivalent,29773029,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1444.00,10/21/2013,Cash or cash equivalent,29761271,Non-Covered Product,,PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492769,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492765,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492762,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492760,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492768,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492757,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492755,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492750,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492720,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492721,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492740,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492741,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492738,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492733,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492774,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492761,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492756,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492748,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492778,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492739,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD ST.,,DAVENPORT,52803,,,TERUMO MEDICAL CORPORATION,100000000291,Terumo Medical Corporation,NJ,84.00,12/23/2013,Cash or cash equivalent,159839362,,,TMC STUDY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492773,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492729,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,701 10th St Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,5000.00,11/25/2013,Cash or cash equivalent,105886136,,,PRESTIGE LP,,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD ST.,,DAVENPORT,52803,,,TERUMO MEDICAL CORPORATION,100000000291,Terumo Medical Corporation,NJ,24.50,09/23/2013,Cash or cash equivalent,159839098,,,TMC STUDY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492754,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492722,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492734,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492732,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492724,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492766,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492764,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492725,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492751,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492749,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492746,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492745,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,201 Gilmore Hall,,Iowa City,52242,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,3330.00,10/23/2013,Cash or cash equivalent,105886134,,,Prestige LP-2,,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD ST.,,DAVENPORT,52803,,,TERUMO MEDICAL CORPORATION,100000000291,Terumo Medical Corporation,NJ,819.12,12/23/2013,Cash or cash equivalent,159839367,,,TMC STUDY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492767,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492777,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492743,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492737,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492731,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD ST.,,DAVENPORT,52803,,,TERUMO MEDICAL CORPORATION,100000000291,Terumo Medical Corporation,NJ,3440.16,09/23/2013,Cash or cash equivalent,159839092,,,TMC STUDY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492753,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492744,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492726,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492742,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,TERUMO MEDICAL CORPORATION,100000000291,Terumo Medical Corporation,NJ,1191.25,09/23/2013,Cash or cash equivalent,24580144,,,TMC STUDY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492736,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492730,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,38.06,09/26/2013,In-kind items and services,14492763,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,451 Newton Road,,Iowa City,52242,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,103.13,08/08/2013,In-kind items and services,14492752,SEP225289,,Adult Attention Deficit Hyperactivity Disorder,,
Non-covered Recipient Entity,,,,,,,8421 PLUM DR,,URBANDALE,50322,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2788.00,08/14/2013,Cash or cash equivalent,29765291,Non-Covered Product,,SUNDIAL,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,600.00,11/26/2013,Cash or cash equivalent,29769409,Non-Covered Product,,METMAB PHIII NSCLC,,
Covered Recipient Teaching Hospital,342,Mercy Health Services/Iowa Corp.,,,,,1000 4th St SW,SUITE IOPT,Mason City,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,725.63,11/12/2013,Cash or cash equivalent,29771037,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,30529.10,09/19/2013,Cash or cash equivalent,29765076,Non-Covered Product,,MOSAIC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,445.00,12/19/2013,Cash or cash equivalent,29774240,GAZYVA,,PH II FL DLBCL SINGLE ARM G-CHOP,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3207.00,08/23/2013,Cash or cash equivalent,29763102,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/26/2013,Cash or cash equivalent,29767341,Non-Covered Product,,METMAB PHIII NSCLC,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4119.00,11/01/2013,Cash or cash equivalent,29759897,Rituxan,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,7182.00,11/13/2013,Cash or cash equivalent,29765649,Non-Covered Product,,MOSAIC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,940.50,09/18/2013,Cash or cash equivalent,29772912,GAZYVA,,PH II FL DLBCL SINGLE ARM G-CHOP,,
Non-covered Recipient Entity,,,,,,,3530 W 4TH ST,,WATERLOO,50701,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,11/04/2013,Cash or cash equivalent,29768072,Non-Covered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,PHYSICIANS RELIANCE NETWORK,,CEDAR RAPIDS,52403,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,7718.02,11/15/2013,Cash or cash equivalent,29770501,Herceptin,,TPAS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,9500.00,11/04/2013,Cash or cash equivalent,29765763,Non-Covered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/16/2013,Cash or cash equivalent,29767566,Non-Covered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,09/04/2013,Cash or cash equivalent,29767731,Non-Covered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,3530 W 4TH ST,,WATERLOO,50701,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,10/02/2013,Cash or cash equivalent,29768040,Non-Covered Product,,NLCS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/16/2013,Cash or cash equivalent,29767347,Non-Covered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4750.00,11/04/2013,Cash or cash equivalent,29765750,Non-Covered Product,,NLCS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2456.25,09/16/2013,Cash or cash equivalent,29772812,Perjeta,,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB&PERTUZUMAB,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2983.00,11/15/2013,Cash or cash equivalent,29770241,Herceptin,,TPAS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,08/16/2013,Cash or cash equivalent,29767570,Non-Covered Product,,METMAB PHIII NSCLC,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3149.10,11/08/2013,Cash or cash equivalent,29767703,Non-Covered Product,,SAFETY STUDY IN PEDIATRIC FXS,,
Non-covered Recipient Entity,,,,,,,PO BOX 1408,,CEDAR RAPIDS,52406-1408,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,750.00,10/25/2013,Cash or cash equivalent,29765406,Non-Covered Product,,MOSAIC,,
Covered Recipient Teaching Hospital,579,Covenant Medical Center Inc,,,,,3421 W 9th St,,Waterloo,50702,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,208.80,11/08/2013,Cash or cash equivalent,29770214,Avastin,,"A randomized, Double-BLIND, Placebo-controlled, phase IIIb trial comparing BEVACIZUMAB therapy WITH OR WITHOUT ERLotInib AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB for the first-line treatment of Locally Advanced, Recurrent, or metastatic nON",,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2166.98,08/07/2013,Cash or cash equivalent,29766123,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,40.23,09/23/2013,Cash or cash equivalent,29773025,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4100.00,11/01/2013,Cash or cash equivalent,29769407,Non-Covered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,800.00,10/10/2013,Cash or cash equivalent,29767010,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,224.33,08/02/2013,Cash or cash equivalent,29769790,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,13100.00,12/02/2013,Cash or cash equivalent,29776371,Perjeta,,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB&PERTUZUMAB,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4790.70,08/07/2013,Cash or cash equivalent,29762278,Zelboraf,,ZELBORAF ROLLOVER STUDY,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1444.33,12/19/2013,Cash or cash equivalent,29767336,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4812.30,12/18/2013,Cash or cash equivalent,29765157,Non-Covered Product,,CV OUTCOME TRIAL 2,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,100.13,11/20/2013,Cash or cash equivalent,29771902,Non-Covered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1500.00,11/04/2013,Cash or cash equivalent,29766327,Non-Covered Product,,NLCS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,9479.00,09/19/2013,Cash or cash equivalent,29761231,Non-Covered Product,,SUB-OPTIMALLY CONTROLLED PTS WITH SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,140.80,08/19/2013,Cash or cash equivalent,29774443,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3000.00,08/02/2013,Cash or cash equivalent,29768446,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,310.00,11/22/2013,Cash or cash equivalent,29770544,Herceptin,,TPAS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,100.57,09/23/2013,Cash or cash equivalent,29773022,Perjeta,,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1215.00,12/06/2013,Cash or cash equivalent,29765963,Non-Covered Product,,MOSAIC,,
Non-covered Recipient Entity,,,,,,,PHYSICIANS RELIANCE NETWORK,,CEDAR RAPIDS,52403,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2983.00,11/15/2013,Cash or cash equivalent,29770503,Herceptin,,TPAS,,
Covered Recipient Teaching Hospital,573,Central Iowa Hospital Corporation,,,,,700 E University Ave,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,5000.00,10/02/2013,Cash or cash equivalent,105925107,,,ADVANCE CRT Registry,,
Non-covered Recipient Entity,,,,,,,28 BBE,,IOWA CITY,52242-1324,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,11675.00,10/09/2013,Cash or cash equivalent,28847317,SGN35,,SG0350014,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,4673.00,08/22/2013,Cash or cash equivalent,105995941,Ranexa,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF RANOLAZINE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH A HISTORY OF CHRONIC ANGINA WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION WITH INCOMPLETE REVASCULARIZATION",,GS-US-259-0116
Covered Recipient Teaching Hospital,582,State University of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Haag-Streit USA, Inc.",100000010377,"Haag-Streit USA, Inc.",OH,470.00,10/25/2013,Cash or cash equivalent,164295452,,,Muscle Activity and Posture During Clinical Ophthalmologic Practice,,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,4000.00,12/20/2013,Cash or cash equivalent,169009628,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,1274.40,09/20/2013,Cash or cash equivalent,169009620,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,C-O GRANT ACCOUNTING OFFICE,B5 JESSUP HALL,IOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,1331.25,08/22/2013,Cash or cash equivalent,114588926,Letairis,,"AMBITION- A RANDOMISED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",,GS-US-300-0140
Covered Recipient Teaching Hospital,582,State University of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Reliance Medical Products, Inc.",100000000321,"Reliance Medical Products, Inc.",OH,470.00,10/25/2013,Cash or cash equivalent,164472138,,,Muscle Activity and Posture During Clinical Ophthalmologic Practice,,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,3325.70,12/20/2013,Cash or cash equivalent,169009624,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803-2459,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,2382.50,08/08/2013,Cash or cash equivalent,23293541,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1062.50,11/25/2013,Cash or cash equivalent,29336454,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,950.94,09/17/2013,Cash or cash equivalent,29336428,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,148.75,10/11/2013,Cash or cash equivalent,29335494,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,09/17/2013,Cash or cash equivalent,29335488,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,785.31,09/17/2013,Cash or cash equivalent,29335480,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,1332.00,10/07/2013,Cash or cash equivalent,106032380,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,42.50,11/25/2013,Cash or cash equivalent,29335504,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,2500.00,10/29/2013,Cash or cash equivalent,29335479,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,170.00,11/25/2013,Cash or cash equivalent,29335509,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2600 Grand Avenueneue,Suite 400,Des Moines,50312,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,12850.00,11/21/2013,Cash or cash equivalent,29338123,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,871.25,11/25/2013,Cash or cash equivalent,29335492,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,10/29/2013,Cash or cash equivalent,29335501,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Drive,,Iowa City,52242,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,2000.00,10/25/2013,Cash or cash equivalent,29337988,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,900.00,08/08/2013,Cash or cash equivalent,106032377,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,2340.00,09/03/2013,Cash or cash equivalent,106032379,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803-2459,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,1000.00,11/04/2013,Cash or cash equivalent,106030945,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Non-covered Recipient Entity,,,,,,,2600 Grand Avenueneue,Suite 400,Des Moines,50312,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,140.00,12/05/2013,Cash or cash equivalent,29338187,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2600 Grand Avenueneue,Suite 400,Des Moines,50312,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,237.00,09/06/2013,Cash or cash equivalent,29337824,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803-2459,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,583.75,12/02/2013,Cash or cash equivalent,106030946,,,SUPERNOVA,,SUPERNOVA
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,148.75,11/25/2013,Cash or cash equivalent,29336453,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,09/17/2013,Cash or cash equivalent,29336443,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,2500.00,11/25/2013,Cash or cash equivalent,29336444,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,11/25/2013,Cash or cash equivalent,29336451,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,148.75,11/25/2013,Cash or cash equivalent,29335507,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,2500.00,09/27/2013,Cash or cash equivalent,29336433,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,345.32,09/17/2013,Cash or cash equivalent,29336430,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,170.00,11/25/2013,Cash or cash equivalent,29335512,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,10/11/2013,Cash or cash equivalent,29335506,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,11/25/2013,Cash or cash equivalent,29336456,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,818.12,10/11/2013,Cash or cash equivalent,29335498,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1062.50,11/25/2013,Cash or cash equivalent,29335508,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,11/08/2013,Cash or cash equivalent,29336449,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1500.00,08/19/2013,Cash or cash equivalent,29336429,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,11/25/2013,Cash or cash equivalent,29336457,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,09/27/2013,Cash or cash equivalent,29336440,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,09/27/2013,Cash or cash equivalent,29336442,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,511.54,08/30/2013,Cash or cash equivalent,29336435,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1500.00,09/27/2013,Cash or cash equivalent,29335490,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,11/25/2013,Cash or cash equivalent,29336450,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,950.94,11/25/2013,Cash or cash equivalent,29336438,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1500.00,08/19/2013,Cash or cash equivalent,29336431,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,345.31,11/25/2013,Cash or cash equivalent,29335486,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,345.31,10/29/2013,Cash or cash equivalent,29335491,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,09/27/2013,Cash or cash equivalent,29336439,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme St,,Davenport,52803-2459,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,905.00,09/03/2013,Cash or cash equivalent,106030944,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,950.94,10/18/2013,Cash or cash equivalent,29336432,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2600 Grand Avenueneue,Suite 400,Des Moines,50312,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,339.00,12/05/2013,Cash or cash equivalent,29338186,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,148.75,11/25/2013,Cash or cash equivalent,29335511,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,11/08/2013,Cash or cash equivalent,29335487,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,09/17/2013,Cash or cash equivalent,29335481,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,170.00,11/25/2013,Cash or cash equivalent,29336452,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,09/17/2013,Cash or cash equivalent,29335500,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,148.75,11/25/2013,Cash or cash equivalent,29335503,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,10/11/2013,Cash or cash equivalent,29335502,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,532.00,12/02/2013,Cash or cash equivalent,106032383,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,818.12,09/17/2013,Cash or cash equivalent,29336436,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,11/25/2013,Cash or cash equivalent,29335510,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,09/27/2013,Cash or cash equivalent,29336441,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,170.00,11/25/2013,Cash or cash equivalent,29335505,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,42.50,10/11/2013,Cash or cash equivalent,29335496,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,326.00,11/04/2013,Cash or cash equivalent,106032382,,,EVOLVE II SYNERGY IDE,,EVOLVE II SYNERGY IDE
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,11/25/2013,Cash or cash equivalent,29336455,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,10/11/2013,Cash or cash equivalent,29336447,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,818.12,10/11/2013,Cash or cash equivalent,29335489,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,11/25/2013,Cash or cash equivalent,29336446,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,818.12,09/27/2013,Cash or cash equivalent,29335482,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,42.50,09/27/2013,Cash or cash equivalent,29335483,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1062.50,08/30/2013,Cash or cash equivalent,29336434,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,345.32,10/18/2013,Cash or cash equivalent,29336437,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,345.31,11/25/2013,Cash or cash equivalent,29335499,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,09/17/2013,Cash or cash equivalent,29335493,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,10/11/2013,Cash or cash equivalent,29336445,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1062.50,10/11/2013,Cash or cash equivalent,29335495,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1004.06,10/29/2013,Cash or cash equivalent,29335497,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,105 Jessup Hall,,Iowa City,52242-1316,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,500.00,10/11/2013,Cash or cash equivalent,29336448,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,1500.00,09/27/2013,Cash or cash equivalent,29335484,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court,Ste 8,Clive,50325,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,345.31,10/29/2013,Cash or cash equivalent,29335485,Xifaxan 550 mg,,Irritable Bowel Syndrome With Diarrhea Rifaximin Re-Treatment Study,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628604,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628610,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628642,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628672,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628754,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628780,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,29288.00,12/09/2013,Cash or cash equivalent,108628824,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,100.00,12/03/2013,Cash or cash equivalent,108628586,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628636,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628686,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628724,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628762,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628618,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628792,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1064.00,11/12/2013,Cash or cash equivalent,108628812,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1064.00,11/12/2013,Cash or cash equivalent,108628816,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,100.00,12/03/2013,Cash or cash equivalent,108628574,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628626,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628664,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628702,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628734,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628768,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628799,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628596,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628658,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628748,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,609.00,12/03/2013,Cash or cash equivalent,108628806,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628678,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628786,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628652,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628710,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628716,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628730,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.00,11/12/2013,Cash or cash equivalent,108628774,,,DU176b-C-U301,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,4549.90,12/31/2013,In-kind items and services,4808803,,,A 12 Week Multicenter Randomized Double Blind Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long Term Extension Period,http://clinicaltrials.gov/ct2/show/NCT01646177,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,11088.85,10/29/2013,Cash or cash equivalent,4805681,,,A Randomized Double Blind Placebo Controlled Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy,http://clinicaltrials.gov/ct2/show/NCT01865084,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,70326.00,08/13/2013,Cash or cash equivalent,4805684,,,A Multicenter Randomized Double Blind Placebo Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma,http://clinicaltrials.gov/ct2/show/NCT01602224,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE STE 285,,CEDAR RAPIDS,52403,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,36443.00,08/13/2013,Cash or cash equivalent,4808086,,,A Multicenter Randomized Double Blind Placebo Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma,http://clinicaltrials.gov/ct2/show/NCT01602224,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,6000.00,08/07/2013,Cash or cash equivalent,4808584,,,A Multicenter Randomized Double Blind Active and Placebo Controlled 24 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab - LY2439821 - in Biologic Disease Modifying Antirheumatic Drug Naive Patients With Active Psoriatic Arthritis,http://clinicaltrials.gov/ct2/show/NCT01695239,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,3912.35,08/22/2013,In-kind items and services,4805688,,,A Phase 2 Efficacy and Safety Dose Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia,http://clinicaltrials.gov/ct2/show/NCT01890967,
Covered Recipient Physician,,,211123,ANUJ,,BHARGAVA,411 LAUREL ST,SUITE 3262,DES MOINES,50314,Medical Doctor,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,52.00,12/31/2013,In-kind items and services,105731344,AXIRON,,A Randomized Double Blind Placebo Controlled Parallel Study With an Open Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone Sex Drive and Energy in Hypogonadal Men,http://clinicaltrials.gov/ct2/show/NCT01816295,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,134675.00,10/03/2013,Cash or cash equivalent,4808802,,,A 12 Week Multicenter Randomized Double Blind Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long Term Extension Period,http://clinicaltrials.gov/ct2/show/NCT01646177,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,135.00,12/31/2013,In-kind items and services,4805683,,,Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study,http://clinicaltrials.gov/ct2/show/NCT02008357,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,105769.78,08/13/2013,Cash or cash equivalent,4805687,,,A Phase 2 Efficacy and Safety Dose Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia,http://clinicaltrials.gov/ct2/show/NCT01890967,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,2900.00,09/17/2013,Cash or cash equivalent,4809959,,,A Randomized Double Blind Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non Small Cell Lung Cancer Following Disease Progression After One Prior Platinum Based Therapy,http://clinicaltrials.gov/ct2/show/NCT01168973,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,927.00,12/31/2013,In-kind items and services,4808583,,,A Multicenter Randomized Double Blind Active and Placebo Controlled 24 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab - LY2439821 - in Biologic Disease Modifying Antirheumatic Drug Naive Patients With Active Psoriatic Arthritis,http://clinicaltrials.gov/ct2/show/NCT01695239,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,801.00,12/31/2013,In-kind items and services,4805685,,,A Multicenter Randomized Double Blind Placebo Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma,http://clinicaltrials.gov/ct2/show/NCT01602224,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,72.90,10/07/2013,Cash or cash equivalent,4806763,,,A PROSPECTIVE MULTI-CENTER RANDOMIZED DOUBLE-BLIND TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF 12 VERSUS 30 MONTHS OF DUAL ANTIPLATELET THERAPY -DAPT- IN SUBJECTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION -PCI- WITH EITHER DRUG-ELUTING STENT -DES- OR BARE METAL STENT -BMS- PLACEMENT FOR THE TREATMENT OF CORONARY ARTERY LESIONS,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000066,"LILLY USA, LLC",IN,725.00,10/08/2013,Cash or cash equivalent,4805682,HUMATROPE,,The Genetics and Neuroendocrinology of Short Stature International Study -GeNeSIS,http://clinicaltrials.gov/ct2/show/NCT01088412,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,1491.00,12/31/2013,In-kind items and services,4805680,,,A Randomized Double Blind Placebo Controlled Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy,http://clinicaltrials.gov/ct2/show/NCT01865084,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,406.12,12/31/2013,In-kind items and services,4808495,,,A Multicenter Randomized Double-Blind Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab -LY2439821- in Patients With Active Ankylosing Spondylitis,http://clinicaltrials.gov/ct2/show/NCT01870284,
Covered Recipient Teaching Hospital,572,CATHOLIC HEALTH INITIATIVES IOWA CORP,,,,,1111 6TH AVE,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,583.71,10/07/2013,Cash or cash equivalent,4805678,,,A PROSPECTIVE MULTI-CENTER RANDOMIZED DOUBLE-BLIND TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF 12 VERSUS 30 MONTHS OF DUAL ANTIPLATELET THERAPY -DAPT- IN SUBJECTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION -PCI- WITH EITHER DRUG-ELUTING STENT -DES- OR BARE METAL STENT -BMS- PLACEMENT FOR THE TREATMENT OF CORONARY ARTERY LESIONS,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720450,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,12/20/2013,In-kind items and services,11720453,Nplate,,"Pediatric ITP, P3",,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,295.00,08/13/2013,In-kind items and services,11678511,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,5417.00,08/01/2013,Cash or cash equivalent,105889368,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,12933.00,08/01/2013,Cash or cash equivalent,105888346,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,6532.00,11/07/2013,Cash or cash equivalent,105888349,,,CoreValve CAS,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,107559.36,09/17/2013,In-kind items and services,11718825,Nplate,,"Pediatric ITP, P3",,
Non-covered Recipient Entity,,,,,,,202 10TH ST S E,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,585.90,12/11/2013,Cash or cash equivalent,11645539,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,42.00,09/09/2013,In-kind items and services,11626353,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/17/2013,In-kind items and services,11626361,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,475.00,12/16/2013,Cash or cash equivalent,105888916,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,11/03/2013,In-kind items and services,11678521,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,648.00,11/13/2013,Cash or cash equivalent,105887524,,,CoreValve U.S. IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,16239.50,12/17/2013,Cash or cash equivalent,105889142,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,990.00,10/17/2013,Cash or cash equivalent,105888915,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1300.00,11/06/2013,In-kind items and services,11720443,Aranesp,,Peds De novo Q2W Aranesp correction,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695520,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695524,XGEVA,,P3 Adjuvant Breast Cancer,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720448,Nplate,,"Pediatric ITP, P3",,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,695.00,08/13/2013,In-kind items and services,11678510,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4795.00,08/02/2013,Cash or cash equivalent,105887521,,,CoreValve U.S. IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,270.00,11/19/2013,Cash or cash equivalent,105888989,,,CoreValve EUS,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1845.70,08/02/2013,Cash or cash equivalent,11626351,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,65.43,10/22/2013,In-kind items and services,11720440,Aranesp,,Peds De novo Q2W Aranesp correction,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4795.00,08/02/2013,Cash or cash equivalent,105887522,,,CoreValve U.S. IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,21855.00,09/26/2013,Cash or cash equivalent,105889141,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,648.00,11/13/2013,Cash or cash equivalent,105887523,,,CoreValve U.S. IDE,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,12933.00,08/01/2013,Cash or cash equivalent,105888347,,,CoreValve CAS,,
Covered Recipient Physician,,,451716,DANIEL,,DIEKEMA,200 HAWKINS DR,UNIVERSITY OF IOWA,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,1555.63,10/15/2013,In-kind items and services,111722328,MYCAMINE,,Prospective Antifungal Therapy Alliance which includes surveillance of invasive fungal infections IFIs among patients hospitalized at 25 medical centers in North America between 2004 and 2008,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,7680.00,12/04/2013,Cash or cash equivalent,12860880,,,Protect CA,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,21855.00,09/26/2013,Cash or cash equivalent,105889140,,,CoreValve SURTAVI,,
Covered Recipient Physician,,,1314483,MICHAEL,ANDY,PFALLER,2026 RIDGEWAY DR,,IOWA CITY,52245,Medical Doctor,Allopathic & Osteopathic Physicians|Pathology|Anatomic Pathology & Clinical Pathology,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,1555.63,10/15/2013,In-kind items and services,111722396,MYCAMINE,,Prospective Antifungal Therapy Alliance which includes surveillance of invasive fungal infections IFIs among patients hospitalized at 25 medical centers in North America between 2004 and 2008,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,6532.00,11/07/2013,Cash or cash equivalent,105888348,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,16239.50,12/17/2013,Cash or cash equivalent,105889143,,,CoreValve SURTAVI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,8529.00,10/24/2013,Cash or cash equivalent,111722454,VESIcare,,A Randomized Double Blind Parallel Placebo Controlled Phase 4 Multicenter Study to Assess Efficacy and Safety of VESIcare Solifenacin Succinate to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy,,
Covered Recipient Teaching Hospital,582,State University of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,2750.00,08/12/2013,Cash or cash equivalent,24591397,Kuvan Tablets,,"PKUDOS PKU Demographics, Outcomes, and Safety Registry",,Registry
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,270.00,11/19/2013,Cash or cash equivalent,105888988,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,,WEST DES MOINES,50266,,,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,9063.00,10/24/2013,Cash or cash equivalent,111722554,VESIcare,,A Randomized Double Blind Parallel Placebo Controlled Phase 4 Multicenter Study to Assess Efficacy and Safety of VESIcare Solifenacin Succinate to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,76.00,10/31/2013,Cash or cash equivalent,105889370,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,496.00,09/26/2013,Cash or cash equivalent,105889369,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,,WEST DES MOINES,50266,,,Astellas Pharma Global Development,100000005406,Astellas Pharma Global Development,IL,5261.00,10/17/2013,Cash or cash equivalent,111718022,XTANDI,,A Randomized Double Blind Phase II Efficacy and Safety Study of MDV3100 ASP9785 vs Bicalutamide in Castrate Men with Metastatic Prostate Cancer,,
Covered Recipient Teaching Hospital,582,State University of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,2500.00,11/07/2013,Cash or cash equivalent,24591399,Kuvan Tablets,,"PKUDOS PKU Demographics, Outcomes, and Safety Registry",,Registry
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,50.00,09/19/2013,Cash or cash equivalent,12860881,,,Protect CA,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,832.00,12/20/2013,Cash or cash equivalent,12859921,,,Miracle Mid EF,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/13/2013,In-kind items and services,11695528,XGEVA,,P3 Adjuvant Breast Cancer,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,12/20/2013,In-kind items and services,11720452,Nplate,,"Pediatric ITP, P3",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1300.00,11/25/2013,In-kind items and services,11720441,Aranesp,,NSCLC,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,SUITE 165,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,40.00,09/11/2013,In-kind items and services,11695518,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,342,MERCY HEALTH SERVICES/IOWA CORP.,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,40.00,09/11/2013,In-kind items and services,11623517,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,342,MERCY HEALTH SERVICES/IOWA CORP.,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,267.00,09/16/2013,Cash or cash equivalent,11623518,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3334.78,09/09/2013,In-kind items and services,11626352,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695519,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695522,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR.,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,150.00,11/14/2013,Cash or cash equivalent,137970030,Sensipar,,Prospective cohort study to describe practice patterns and safety events in pediatric dialysis patients treated and not treated with cinacalcet in the NAPRTCS registry,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,41.67,09/01/2013,In-kind items and services,137963516,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1.65,08/01/2013,In-kind items and services,137962512,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2.92,09/16/2013,In-kind items and services,137960548,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,41.67,10/01/2013,In-kind items and services,137964556,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2.92,08/22/2013,In-kind items and services,137960542,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1.65,12/01/2013,In-kind items and services,137966486,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,120.19,10/08/2013,In-kind items and services,137960574,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1.65,10/01/2013,In-kind items and services,137964554,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,41.67,11/01/2013,In-kind items and services,137965540,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1.65,09/01/2013,In-kind items and services,137963514,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,41.67,08/01/2013,In-kind items and services,137962514,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2.92,09/16/2013,In-kind items and services,137967504,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,120.19,08/22/2013,In-kind items and services,137967488,Neulasta,,Bone Pain Educational Tool US VINE study,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1667.39,12/02/2013,In-kind items and services,11626357,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/13/2013,In-kind items and services,11695527,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,11/17/2013,In-kind items and services,11678526,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/24/2013,In-kind items and services,11678519,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,838.40,12/11/2013,Cash or cash equivalent,11706066,Neulasta,,Bone Pain Management US NOLAN study,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1300.00,08/29/2013,In-kind items and services,11720442,Sensipar,,"Pediatric 26week, Time until Transplant",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720444,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720445,Nplate,,"Pediatric ITP, P3",,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/05/2013,In-kind items and services,11678501,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,08/05/2013,In-kind items and services,11678507,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,08/05/2013,In-kind items and services,11678509,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/23/2013,In-kind items and services,11678514,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/23/2013,In-kind items and services,11678517,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1667.39,09/04/2013,In-kind items and services,11695317,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,"200 HAWKINS DR, SE 313 GH",,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,17.37,08/11/2013,In-kind items and services,11669863,Aranesp,,NSCLC,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,08/23/2013,In-kind items and services,11695529,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/24/2013,In-kind items and services,11678518,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,328.50,09/12/2013,Cash or cash equivalent,11678513,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,603.80,10/22/2013,Cash or cash equivalent,11695530,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/05/2013,In-kind items and services,11678502,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/05/2013,In-kind items and services,11678506,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1007.80,10/30/2013,Cash or cash equivalent,11706065,Neulasta,,Bone Pain Management US NOLAN study,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3993.00,09/13/2013,Cash or cash equivalent,11706064,Neulasta,,Bone Pain Management US NOLAN study,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,12170.00,08/02/2013,Cash or cash equivalent,11626350,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,350.00,10/04/2013,Cash or cash equivalent,11626356,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1667.39,12/02/2013,In-kind items and services,11626358,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,42.00,12/02/2013,In-kind items and services,11626359,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1.65,11/01/2013,In-kind items and services,137965538,Aranesp,,Aranesp START CKD,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/17/2013,In-kind items and services,11626362,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/05/2013,In-kind items and services,11678499,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,77.75,11/06/2013,In-kind items and services,11678523,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,7.50,11/06/2013,In-kind items and services,11678524,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,08/18/2013,In-kind items and services,11678512,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695523,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,11/10/2013,In-kind items and services,11678525,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1667.39,12/02/2013,In-kind items and services,11695318,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,11/03/2013,In-kind items and services,11678522,Aranesp,,Aranesp START CKD,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,375.00,12/31/2013,In-kind items and services,180193314,,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY,http://clinicaltrials.gov/ct2/show/NCT01865084,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR"
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,41.67,12/01/2013,In-kind items and services,137966488,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,120.19,10/08/2013,In-kind items and services,137967536,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2.92,08/22/2013,In-kind items and services,137967490,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE,NORTHEAST 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,120.19,08/22/2013,In-kind items and services,137960540,Neulasta,,Bone Pain Educational Tool US VINE study,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,118235.00,12/16/2013,Cash or cash equivalent,180196798,,,A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD,http://clinicaltrials.gov/ct2/show/NCT01646177,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR"
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,ELI LILLY AND COMPANY,IN,585.00,12/31/2013,In-kind items and services,180191510,,,A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD,http://clinicaltrials.gov/ct2/show/NCT01646177,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR"
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695521,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/13/2013,In-kind items and services,11695526,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/24/2013,In-kind items and services,11678520,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,08/04/2013,In-kind items and services,11678532,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,351.08,09/13/2013,Cash or cash equivalent,11626354,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2750.00,09/13/2013,Cash or cash equivalent,11626355,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/23/2013,In-kind items and services,11678515,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/23/2013,In-kind items and services,11678516,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/05/2013,In-kind items and services,11678500,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/05/2013,In-kind items and services,11678504,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/05/2013,In-kind items and services,11678505,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,08/05/2013,In-kind items and services,11678508,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,202 10TH ST.  SE,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,08/13/2013,In-kind items and services,11695525,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,"200 HAWKINS DR, SE 313 GH",,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,08/04/2013,In-kind items and services,11669861,Aranesp,,NSCLC,,
Non-covered Recipient Entity,,,,,,,"200 HAWKINS DR, SE 313 GH",,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,08/04/2013,In-kind items and services,11669862,Aranesp,,NSCLC,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720446,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720447,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720449,Nplate,,"Pediatric ITP, P3",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/20/2013,In-kind items and services,11720451,Nplate,,"Pediatric ITP, P3",,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,08/05/2013,In-kind items and services,11678503,Aranesp,,Aranesp START CKD,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,12/17/2013,In-kind items and services,11626360,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Physician,,,12930,BRUCE,,HUGHES,1111 6TH AVE,EAST TOWER SUITE A100,DES MOINES,50314-2610,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1567.00,11/30/2013,In-kind items and services,23928254,GILENYA,,RESEARCH RELATED PUBLICATION SUPPORT,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4662,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2470.00,09/20/2013,Cash or cash equivalent,154490684,TEKTURNA,,AN 12 WEEK MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE CONTROL PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF VALTURNA ALISKIREN 300 MG PER VALSARTAN 320 MG AND AMOLODIPINE 10 MG VERSUS VALTURNA ALONE ALISKIREN 300 MG PER VALSARTAN 320 MG IN PATIENTS WITH STAGE 2 HYPERTENSION AND DIABETES,,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,,CEDAR RAPIDS,52403-2414,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2961.00,10/10/2013,Cash or cash equivalent,23930304,COSENTYX,,A RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED  MULTICENTER STUDY OF SECUKINUMAB TO DEMONSTRATE THE EFFICACY AT 16 WEEKS AND TO ASSESS THE LONG TERM SAFETY  TOLERABILITY AND EFFICACY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702-5014,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,11162.79,08/01/2013,In-kind items and services,23930800,ILARIS,,A RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED  EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314-2610,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,9777.24,08/05/2013,Cash or cash equivalent,23930303,GILENYA,,LONG TERM  PROSPECTIVE  MULTINATIONAL  PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,58033.29,10/07/2013,In-kind items and services,23931702,TASIGNA,,PHASE II STUDY OF MMR RATES FOLLOWING NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR4 5 FOR 1 VERSUS 2 YEARS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,FL 2,AMES,50010-5400,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1333.14,08/01/2013,In-kind items and services,23930506,ILARIS,,A RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED  EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE CC10,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,9059.40,12/13/2013,In-kind items and services,154493235,TOBI PODHALER,,A 24 WEEK OPEN LABEL PARALLEL GROUP INTERVENTIONAL PHASE IV STUDY COMPARING TOBRAMYCIN INHALATION POWDER TIP ADMINISTERED ONCE DAILY CONTINUOUSLY VERSUS TIP ADMINISTERED BID IN 28 DAY ON AND OR 28 DAY OFF CYCLES FOR THE TREATMENT OF PULMONARY PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS,,
Non-covered Recipient Entity,,,,,,,1600 DIAMOND ST,,ONAWA,51040-1548,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,386.25,08/01/2013,In-kind items and services,154493240,EXJADE,,A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Ste. 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,12965.40,08/27/2013,Cash or cash equivalent,106108568,Hylenex,,CONSISTENT 1- Evaluation of Metabolic Outcomes and Safery of Hylenex Recombinant Hyaluronidase Human Injection- Used as a Preadministration Infusion Site Treatment in Subjects with Type 1 Diabetes -T1DM- Using Continuous Subcutaneous Insulin Infusion-CSII,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,20573.20,12/06/2013,Cash or cash equivalent,106108949,Hylenex,,CONSISTENT 1- Evaluation of Metabolic Outcomes and Safery of Hylenex Recombinant Hyaluronidase Human Injection- Used as a Preadministration Infusion Site Treatment in Subjects with Type 1 Diabetes -T1DM- Using Continuous Subcutaneous Insulin Infusion-CSII,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Ste.3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,37219.10,10/01/2013,Cash or cash equivalent,106108706,Hylenex,,CONSISTENT 1- Evaluation of Metabolic Outcomes and Safery of Hylenex Recombinant Hyaluronidase Human Injection- Used as a Preadministration Infusion Site Treatment in Subjects with Type 1 Diabetes -T1DM- Using Continuous Subcutaneous Insulin Infusion-CSII,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Ste. 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,19087.95,09/10/2013,Cash or cash equivalent,106108574,Hylenex,,CONSISTENT 1- Evaluation of Metabolic Outcomes and Safery of Hylenex Recombinant Hyaluronidase Human Injection- Used as a Preadministration Infusion Site Treatment in Subjects with Type 1 Diabetes -T1DM- Using Continuous Subcutaneous Insulin Infusion-CSII,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Ste.3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,10957.30,10/29/2013,Cash or cash equivalent,106108721,Hylenex,,CONSISTENT 1- Evaluation of Metabolic Outcomes and Safery of Hylenex Recombinant Hyaluronidase Human Injection- Used as a Preadministration Infusion Site Treatment in Subjects with Type 1 Diabetes -T1DM- Using Continuous Subcutaneous Insulin Infusion-CSII,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Shire US Holdings,100000000241,Shire US Holdings,PA,51540.00,09/25/2013,Cash or cash equivalent,105770354,,,,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE CC10,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,386.25,08/01/2013,In-kind items and services,163446704,ZYKADIA,,A PHASE II MULTICENTER SINGLE ARM STUDY OF ORAL LDK378 IN CRIZOTINIB NAIVE ADULT PATIENTS WITH ALK ACTIVATED NON SMALL CELL LUNG CANCER,,
Non-covered Recipient Entity,,,,,,,210 E IOWA AVE,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,253668.96,08/01/2013,In-kind items and services,23931704,TASIGNA,,A PHASE III MULTI CENTER  OPEN LABEL  RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE  PHPLUS  CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE  CML CP,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2400.00,08/31/2013,Cash or cash equivalent,23931703,TASIGNA,,PHASE II STUDY OF MMR RATES FOLLOWING NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR4 5 FOR 1 VERSUS 2 YEARS,,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,,CEDAR RAPIDS,52403-2414,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,7258.25,08/01/2013,In-kind items and services,23930305,COSENTYX,,A RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED  MULTICENTER STUDY OF SECUKINUMAB TO DEMONSTRATE THE EFFICACY AT 16 WEEKS AND TO ASSESS THE LONG TERM SAFETY  TOLERABILITY AND EFFICACY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd St,Suite 8,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,3000.00,09/26/2013,Cash or cash equivalent,106684984,Agile Patency Capsule,,MA-209,,
Non-covered Recipient Entity,,,,,,,1378 NW 124th St,Suite 200,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,40952.00,08/02/2013,Cash or cash equivalent,106685030,Agile Patency Capsule,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd St,Suite 8,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,4466.50,11/21/2013,Cash or cash equivalent,106684986,Agile Patency Capsule,,MA-209,,
Non-covered Recipient Entity,,,,,,,1378 NW 124th St,Suite 200,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,97.63,08/19/2013,Cash or cash equivalent,106685034,Agile Patency Capsule,,MA-209,,
Non-covered Recipient Entity,,,,,,,210 E IOWA AVE,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,475.00,08/01/2013,In-kind items and services,23931707,FARYDAK,,EPIGENETIC MODIFICATION OF CHEMOSENSITIVITY AND APOPTOSIS IN METASTATIC MELANOMA TREATMENT OF A RESISTANT DISEASE USING DECITABINE  TEMOZOLOMIDE AND AND PANOBINOSTAT,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,KARLSTORZ Endoscopy-America,100000005515,KARLSTORZ Endoscopy-America,CA,33273.90,08/06/2013,Cash or cash equivalent,106018558,,,Video laryngoscope comparison,,
Non-covered Recipient Entity,,,,,,,1378 NW 124th St,Suite 200,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,1845.00,08/05/2013,Cash or cash equivalent,106685032,Agile Patency Capsule,,MA-209,,
Non-covered Recipient Entity,,,,,,,200 Dawkins Drive,PFP21154 Dept of Otolaryngology,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1265.00,11/11/2013,Cash or cash equivalent,106217584,,,Clinical Study of the Nucleus Hybrid Cochlear Implant HybridS12,,Research fees
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Shire US Holdings,100000000241,Shire US Holdings,PA,5144.96,11/06/2013,Cash or cash equivalent,105770356,,,,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE CC10,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,231.75,11/13/2013,In-kind items and services,163446702,ZYKADIA,,A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242-1007,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,40478.85,11/05/2013,In-kind items and services,163446884,AFINITOR,,A RANDOMIZED DOUBLE BLIND PHASE III STUDY OF RAD001 10 MG PER D PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN THE TREATMENT OF PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMOR NET,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266-8289,,,Warner Chilcott LLC,100000010614,Warner Chilcott LLC,NJ,6840.00,11/26/2013,Cash or cash equivalent,22916160,,,PR-05710,,PR-05710
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266-8289,,,Warner Chilcott LLC,100000010614,Warner Chilcott LLC,NJ,3420.00,12/18/2013,Cash or cash equivalent,22916170,,,PR-05710,,PR-05710
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,2033.00,09/23/2013,Cash or cash equivalent,5079952,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,4318.32,08/20/2013,In-kind items and services,5079954,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,3458.00,11/25/2013,Cash or cash equivalent,5079953,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266-8289,,,Warner Chilcott LLC,100000010614,Warner Chilcott LLC,NJ,1710.00,12/05/2013,Cash or cash equivalent,22916165,,,PR-05710,,PR-05710
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,8227.00,11/20/2013,Cash or cash equivalent,5082479,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,75.00,12/26/2013,Cash or cash equivalent,179315402,NonCovered Product,,SUB-OPTIMALLY CONTROLLED PTS WITH SCHIZOPHRENIA 3,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,6000.00,12/18/2013,Cash or cash equivalent,5082553,TUDORZA,,"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5721.00,12/03/2013,Cash or cash equivalent,179314880,NonCovered Product,,PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5123.00,12/19/2013,Cash or cash equivalent,179315223,NonCovered Product,,PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 3,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,520.30,11/19/2013,In-kind items and services,5082552,TUDORZA,,"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,13353.20,08/07/2013,In-kind items and services,5082480,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,7600.00,09/11/2013,Cash or cash equivalent,5082478,DALIRESP,,"A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 'COPD' TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID 'LABA-ICS'",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,2200.00,09/05/2013,Cash or cash equivalent,5079955,LINZESS,,"PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH CHRONIC CONSTIPATION AND PROMINENT ABDOMINAL BLOATING AT BASELINE",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,,CLIVE,50325,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,133.50,10/31/2013,Cash or cash equivalent,5082034,LINZESS,,"PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH CHRONIC CONSTIPATION AND PROMINENT ABDOMINAL BLOATING AT BASELINE",,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,50.00,12/26/2013,Cash or cash equivalent,179315411,NonCovered Product,,PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,4459.25,10/31/2013,Cash or cash equivalent,5079956,LINZESS,,"PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH CHRONIC CONSTIPATION AND PROMINENT ABDOMINAL BLOATING AT BASELINE",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,,CLIVE,50325,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,806.50,10/31/2013,Cash or cash equivalent,5082035,LINZESS,,"PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH CHRONIC CONSTIPATION AND PROMINENT ABDOMINAL BLOATING AT BASELINE",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266-8289,,,Warner Chilcott LLC,100000010614,Warner Chilcott LLC,NJ,6840.00,12/05/2013,Cash or cash equivalent,22916163,,,PR-05710,,PR-05710
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266-8289,,,Warner Chilcott LLC,100000010614,Warner Chilcott LLC,NJ,6500.00,11/12/2013,Cash or cash equivalent,22916158,,,PR-05710,,PR-05710
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,75.00,12/04/2013,Cash or cash equivalent,179314963,NonCovered Product,,PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,11150.00,12/12/2013,Cash or cash equivalent,179315046,Rituxan,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,11028.00,12/04/2013,Cash or cash equivalent,179314955,NonCovered Product,,SUB-OPTIMALLY CONTROLLED PTS WITH SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2716.00,12/19/2013,Cash or cash equivalent,179315209,NonCovered Product,,SUB-OPTIMALLY CONTROLLED PTS WITH SCHIZOPHRENIA 3,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266-8289,,,Warner Chilcott LLC,100000010614,Warner Chilcott LLC,NJ,3420.00,12/05/2013,Cash or cash equivalent,22916167,,,PR-05710,,PR-05710
Non-covered Recipient Entity,,,,,,,3400 DEXTER CT,,DAVENPORT,52807,,,"Forest Laboratories, Inc.",100000005527,"FOREST RESEARCH INSTITUTE, INC.",NJ,1168.50,10/31/2013,Cash or cash equivalent,5081863,LINZESS,,"PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH CHRONIC CONSTIPATION AND PROMINENT ABDOMINAL BLOATING AT BASELINE",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,177.00,09/16/2013,In-kind items and services,14946237,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,10/22/2013,Cash or cash equivalent,14947266,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,750.00,08/02/2013,Cash or cash equivalent,14947183,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,350.00,10/22/2013,Cash or cash equivalent,14947261,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,187.00,08/20/2013,In-kind items and services,14942374,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1750.00,10/22/2013,Cash or cash equivalent,14947175,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,141.00,12/23/2013,In-kind items and services,14943950,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,300.00,08/02/2013,Cash or cash equivalent,14947184,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1286.01,10/22/2013,Cash or cash equivalent,14938370,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,UNIVERSITY OF IOWA,GRANT ACCOUNTING B5 JESSUP HALL,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1726.00,09/04/2013,Cash or cash equivalent,14936166,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.00,10/24/2013,In-kind items and services,14946090,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.00,08/01/2013,In-kind items and services,14941896,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,08/02/2013,Cash or cash equivalent,14947185,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,14700.00,10/15/2013,Cash or cash equivalent,14937693,,,Eff-IV-NSTEMI with PCI,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,10/22/2013,Cash or cash equivalent,14947174,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,220.00,12/30/2013,In-kind items and services,14943831,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,91.00,08/26/2013,In-kind items and services,14942591,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1750.00,08/02/2013,Cash or cash equivalent,14947182,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C606,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13.00,10/03/2013,In-kind items and services,14945330,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,54150.00,09/09/2013,Cash or cash equivalent,21689432,,,QID01 QID01,,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,461.67,12/31/2013,In-kind items and services,21688705,FLUZONE,,Annual Fluzone Adult Study GRC52,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,LIMITED TO OFFICIAL STATE DUTIES ONLY,"UNIV.OF IA. SW34, GENERAL HOSP",IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,4169.18,12/31/2013,In-kind items and services,21690739,,,H-030-014  Phase III Primary Prevention H-030-014,,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1967.44,12/31/2013,In-kind items and services,21688730,FLUZONE,,Annual Fluzone Adult Study GRC52,,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,461.67,12/31/2013,In-kind items and services,21688706,FLUZONE,,Annual Fluzone Adult Study GRC52,,
Covered Recipient Physician,,,260479,JENNIFER,S,KAY,210 RIDGE RD N STE 201,,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1967.44,12/31/2013,In-kind items and services,21688729,FLUZONE,,Annual Fluzone Adult Study GRC52,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,500.00,09/09/2013,Cash or cash equivalent,21689431,,,QID01 QID01,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13140.00,09/04/2013,Cash or cash equivalent,14941832,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1080.33,11/11/2013,In-kind items and services,14935869,Apidra,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,350.00,08/27/2013,Cash or cash equivalent,14937137,,,LT Safety-IV-Treatment Extension Protocol,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.00,10/18/2013,In-kind items and services,14945440,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,900.00,10/25/2013,Cash or cash equivalent,14936749,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 Pleasant St,,Des Moines,50309,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,4000.00,09/12/2013,Cash or cash equivalent,106160765,Xifaxan 550 mg,,The Safety and Efficacy Of Rifaximin With or Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,443.00,08/19/2013,In-kind items and services,14942867,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.01,08/19/2013,In-kind items and services,14935461,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1080.33,08/12/2013,In-kind items and services,14935825,Apidra,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,585 W CHERRY ST,PO BOX 260,NORTH LIBERTY,52317,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,18.00,09/18/2013,Cash or cash equivalent,14938932,LANTUS,,Diabetes FORWARD,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,10/22/2013,Cash or cash equivalent,14947263,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,10/22/2013,Cash or cash equivalent,14947265,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3500.00,12/23/2013,Cash or cash equivalent,14936527,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C606,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13.00,12/15/2013,In-kind items and services,14943541,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,190.00,12/27/2013,In-kind items and services,14944164,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,220.00,12/31/2013,In-kind items and services,14944169,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,72.60,11/06/2013,In-kind items and services,14936422,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,200.00,09/25/2013,Cash or cash equivalent,14936509,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9000.00,10/15/2013,Cash or cash equivalent,14937725,,,Eff-IV-NSTEMI with PCI,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.34,10/02/2013,In-kind items and services,14935709,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,777.72,10/14/2013,In-kind items and services,14936281,Apidra,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,45.00,10/02/2013,In-kind items and services,14935402,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,UNIVERSITY OF IOWA,GRANT ACCOUNTING B5 JESSUP HALL,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,566.00,12/23/2013,Cash or cash equivalent,14936293,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,304.00,09/18/2013,In-kind items and services,14945792,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,08/02/2013,Cash or cash equivalent,14947186,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,10/22/2013,Cash or cash equivalent,14947264,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,650.00,10/22/2013,Cash or cash equivalent,14947176,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3000.00,08/15/2013,Cash or cash equivalent,14937255,,,Eff-SC-Efficacy -safety in Elderly,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3000.00,10/29/2013,Cash or cash equivalent,14938438,,,LT Safety-IV-Treatment Extension Protocol,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,72.60,08/02/2013,In-kind items and services,14935246,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,74.00,08/21/2013,In-kind items and services,14942456,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1750.00,10/22/2013,Cash or cash equivalent,14947173,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2250.00,09/05/2013,Cash or cash equivalent,14937134,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,48.46,08/19/2013,In-kind items and services,14935202,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,28510.67,08/28/2013,Cash or cash equivalent,16636026,,,Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaDLBCL,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,50512.50,09/25/2013,Cash or cash equivalent,16635913,,,"Assessment of lung structural alterations using high resolution multidetector-row compound tomography before, during , and after acute exacerbations in chronic obstructive pulomanry disease patients, a pilot study.",,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 Pleasant St,,Des Moines,50309,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,650.00,10/03/2013,Cash or cash equivalent,106160900,Xifaxan 550 mg,,The Safety and Efficacy Of Rifaximin With or Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2967.26,09/25/2013,Cash or cash equivalent,16635867,BRILINTA,,"A Randomised, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo in Addition to Existing Acetyl Salicylic Acid ASA Therapy in Patients with History of Myocardial Infarction and Risk of Thrombotic Even",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,10897.29,11/01/2013,In-kind items and services,16635920,FARXIGA,,"Dapagliflozin Effect on Cardiovascular Events  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,1616.61,09/25/2013,In-kind items and services,16636114,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,71.00,11/01/2013,In-kind items and services,14944256,,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,26.00,08/01/2013,In-kind items and services,14941890,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,443.00,10/04/2013,In-kind items and services,14945578,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,603 E 12TH ST STE 284,,DES MOINES,50319,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1382.94,09/23/2013,In-kind items and services,14935947,Apidra,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,47.96,10/02/2013,In-kind items and services,14935484,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1500.00,09/17/2013,Cash or cash equivalent,14937928,,,Eff-SC-Efficacy -safety in Elderly,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,250.00,10/22/2013,Cash or cash equivalent,14947172,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.00,12/23/2013,In-kind items and services,14943992,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,94.00,12/11/2013,In-kind items and services,14942957,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.00,11/27/2013,In-kind items and services,14944533,,,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,551.00,12/16/2013,In-kind items and services,14942930,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1125.00,11/22/2013,Cash or cash equivalent,14937001,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,34.00,08/28/2013,In-kind items and services,14942762,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and -or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR. SE 257 GH,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,69.00,12/17/2013,In-kind items and services,14943097,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,469.00,11/08/2013,In-kind items and services,14944019,,,ODYSSEY Outcomes  Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553  REGN727,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9000.00,09/05/2013,Cash or cash equivalent,14937495,,,Eff-IV-NSTEMI with PCI,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,607.00,08/02/2013,In-kind items and services,14942019,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and -or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients  GetGoal-O,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.00,08/01/2013,In-kind items and services,14941934,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy  EDITION III,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.00,08/26/2013,In-kind items and services,14942551,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1080.33,11/18/2013,In-kind items and services,14935870,Apidra,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,38.34,08/02/2013,In-kind items and services,14935460,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,350.00,10/22/2013,Cash or cash equivalent,14947262,LANTUS,,Edition III,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,95.00,10/17/2013,In-kind items and services,14945316,,,Open Label Study of Long Term Safety Evaluation of Alirocumab  ODYSSEY OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C606,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,35.00,08/30/2013,In-kind items and services,14942561,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17295.00,12/23/2013,Cash or cash equivalent,14941669,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25197.00,10/08/2013,Cash or cash equivalent,14937907,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,246.00,11/21/2013,In-kind items and services,14944476,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,48.46,08/02/2013,In-kind items and services,14935201,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,947.50,10/02/2013,In-kind items and services,14935409,,,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the  efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three  times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or  without metformin",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR  C606,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13.00,12/11/2013,In-kind items and services,14942998,,,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,,
Non-covered Recipient Entity,,,,,,,1030 Browns Woods Drive,,West Des Moines,50265,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1142.00,10/21/2013,Cash or cash equivalent,202410942,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,882.00,11/19/2013,Cash or cash equivalent,202398704,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Non-covered Recipient Entity,,,,,,,1030 Browns Woods Drive,,West Des Moines,50265,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,11/19/2013,Cash or cash equivalent,202410952,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,6661.00,12/02/2013,Cash or cash equivalent,106032384,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1000.00,09/10/2013,Cash or cash equivalent,202410907,TECFIDERA,,A Multicenter  Open Label  12 Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient Reported Outcomes of Oral Tecfidera  dimethyl fumarate  Delayed Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis Af,,
Non-covered Recipient Entity,,,,,,,1440 PLEASANT ST STE 1,,DES MOINES,50314-1728,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,718.00,09/17/2013,Cash or cash equivalent,202405686,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Non-covered Recipient Entity,,,,,,,1030 Browns Woods Drive,,West Des Moines,50265,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1556.00,09/17/2013,Cash or cash equivalent,202410912,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,4732.00,08/19/2013,Cash or cash equivalent,106032378,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY
Non-covered Recipient Entity,,,,,,,1225 S GEAR AVE STE 153,,WEST BURLINGTON,52655-1686,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,75.00,10/16/2013,Cash or cash equivalent,202405568,TYSABRI,,TYSABRI Global Observational Program in Safety,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Ave,,Des Moines,50306-9170,,,Boston Scientific Corporation,100000005674,Boston Scientific Corporation,MA,6206.00,11/04/2013,Cash or cash equivalent,106032381,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY
Non-covered Recipient Entity,,,,,,,1030 Browns Woods Drive,,West Des Moines,50265,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,2375.00,10/16/2013,Cash or cash equivalent,202410918,TYSABRI,,TYSABRI Global Observational Program in Safety,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,896.00,09/17/2013,Cash or cash equivalent,202398684,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,448.00,10/21/2013,Cash or cash equivalent,202398698,TYSABRI,,JCV Antibody Program STRATIFY 2,,
Covered Recipient Teaching Hospital,574,CENTRAL IOWA HOSPITAL CORPORATION,,,,,1200 PLEASANT ST,,DES MOINES,50309-1406,,,Biogen Idec Inc.,100000000193,Biogen Idec Inc.,MA,1939.00,08/02/2013,Cash or cash equivalent,202392858,,,Long Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing Remitting Multiple Sclerosis,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,8555.58,10/02/2013,Cash or cash equivalent,29648965,BioTherapeutics - Research & Development,,NCT01508910,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3000.00,09/25/2013,Cash or cash equivalent,207601602,,,A Trial to Assess the Safety  Tolerability  and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged greater than EQUAL TO18 to less than26 Years,,
Non-covered Recipient Entity,,,,,,,ATTN DR JENNIFER KAY,201 RIDGE STREET,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,178.00,12/09/2013,In-kind items and services,207666174,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000167,Pfizer International LLC,NY,513.00,10/28/2013,Cash or cash equivalent,207460560,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1339.96,12/17/2013,In-kind items and services,207668846,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,412.54,12/20/2013,Cash or cash equivalent,29648964,BioTherapeutics - Research & Development,,NCT01508910,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,1203.14,10/29/2013,Cash or cash equivalent,29648966,BioTherapeutics - Research & Development,,NCT01508910,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,410.00,08/19/2013,Cash or cash equivalent,207481680,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,37039.70,10/25/2013,Cash or cash equivalent,106160959,Solesta,,Long Term Safety and Efficacy of Solesta Injectable Bulking Agent for the Treatment of Fecal Incontinence,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,12/13/2013,In-kind items and services,207468592,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,12/05/2013,Cash or cash equivalent,207476810,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,902.50,09/05/2013,Cash or cash equivalent,207476824,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207480566,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,09/13/2013,In-kind items and services,207477512,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207489920,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,194.00,11/14/2013,Cash or cash equivalent,207476732,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207482652,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,Iowa Digestive Disease Center,1378 NW 124TH ST SUITE 200,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1300.00,09/19/2013,In-kind items and services,207476806,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,08/19/2013,Cash or cash equivalent,207495024,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 W Ridgeway Ave,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5359.84,11/27/2013,In-kind items and services,207668442,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,DR JENNIFER ROBINSON,200 HAWKINS DRIVE E 257GH,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,47.00,12/09/2013,In-kind items and services,207663365,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1331.10,11/25/2013,Cash or cash equivalent,207662472,,,,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,09/12/2013,Cash or cash equivalent,207621420,XELJANZ,,Long Term Effectiveness And Safety Of CP 690 550 For The Treatment Of Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,ATTN DR JENNIFER KAY,201 RIDGE STREET,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,178.00,12/09/2013,In-kind items and services,207660532,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,350.00,12/18/2013,Cash or cash equivalent,207529756,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,205.00,08/19/2013,Cash or cash equivalent,207457868,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,12/18/2013,Cash or cash equivalent,207523664,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,220.00,09/05/2013,Cash or cash equivalent,207499106,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,200.00,08/09/2013,Cash or cash equivalent,207494882,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,08/19/2013,Cash or cash equivalent,207458992,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6.00,08/19/2013,Cash or cash equivalent,207488934,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1733.75,12/19/2013,Cash or cash equivalent,207483460,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,11/14/2013,In-kind items and services,207501336,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207460412,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207459010,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207460516,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,308.00,08/19/2013,Cash or cash equivalent,207460594,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,592.90,11/20/2013,Cash or cash equivalent,207527662,XELJANZ,,A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB CP690550 FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,776.00,08/19/2013,Cash or cash equivalent,207555046,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,114.00,08/19/2013,Cash or cash equivalent,207457460,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1733.75,11/21/2013,Cash or cash equivalent,207561258,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,866.88,12/19/2013,Cash or cash equivalent,207486622,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207494960,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207488892,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,525.00,12/18/2013,Cash or cash equivalent,207458762,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,12/18/2013,Cash or cash equivalent,207460350,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,960.00,09/05/2013,Cash or cash equivalent,207476680,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,42.00,08/19/2013,Cash or cash equivalent,207488932,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,380.00,08/09/2013,Cash or cash equivalent,207521362,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,10/03/2013,Cash or cash equivalent,207538048,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207458990,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,272.40,09/05/2013,Cash or cash equivalent,207559154,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,54.00,08/19/2013,Cash or cash equivalent,207459956,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,525.00,12/18/2013,Cash or cash equivalent,207460032,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,380.00,08/09/2013,Cash or cash equivalent,207458820,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,201 Ridge Street,Suite 201,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,224.36,09/23/2013,In-kind items and services,207470666,,,A PHASE 2 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MCV4 TDAP VACCINE AND BIVALENT RLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY SUBJECTS AGED greater than 10 TO less than13 YEARS,,Study Drug
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1120.00,12/05/2013,Cash or cash equivalent,207491872,SUTENT,,AN OPENLABEL SUNITINIB MALATE SU011248 CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,10/14/2013,In-kind items and services,207491554,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1339.96,10/17/2013,In-kind items and services,207493108,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,10049.70,12/02/2013,In-kind items and services,207552012,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2009.94,11/21/2013,In-kind items and services,207460082,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207536266,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,410.00,08/19/2013,Cash or cash equivalent,207559430,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,669.98,10/23/2013,In-kind items and services,207509424,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1733.75,11/21/2013,Cash or cash equivalent,207476758,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207529914,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,Suite 240,5950 University Ave,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1052.00,08/05/2013,In-kind items and services,207477344,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,Study Drug
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207481564,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1733.75,12/19/2013,Cash or cash equivalent,207512262,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,ATTN DR JENNIFER KAY,201 RIDGE STREET,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1989.00,12/09/2013,In-kind items and services,207665736,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 Pleasant St,,Des Moines,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,600.00,08/27/2013,In-kind items and services,207533674,TYGACIL,ZYVOX,Global Fungal program,,Study Drug
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1225.00,12/24/2013,Cash or cash equivalent,207656761,SUTENT,,An OpenLabel Sunitinib Malate SU011248 Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,09/11/2013,Cash or cash equivalent,207579324,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207457848,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,09/27/2013,Cash or cash equivalent,207567346,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2009.94,12/06/2013,In-kind items and services,207512634,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,230 NE STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,750.00,10/24/2013,Cash or cash equivalent,207625084,,,A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed Refractory Aggressive Non Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High Dose Chemotherapy,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,12/13/2013,In-kind items and services,207516782,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,08/14/2013,In-kind items and services,207563577,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,230 NE STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,250.00,09/05/2013,Cash or cash equivalent,207653050,,,A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed Refractory Aggressive Non Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High Dose Chemotherapy,,
Non-covered Recipient Entity,,,,,,,ATTN DR JENNIFER KAY,201 RIDGE STREET,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,47.00,12/09/2013,In-kind items and services,207661808,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,09/11/2013,Cash or cash equivalent,207567688,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,37.00,08/19/2013,Cash or cash equivalent,207534318,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,08/19/2013,Cash or cash equivalent,207490944,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,460.60,11/20/2013,Cash or cash equivalent,207458378,XELJANZ,,A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB CP690550 FOR TREATMENT OF RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,10/14/2013,In-kind items and services,207518862,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207553002,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,12/18/2013,Cash or cash equivalent,207458668,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,1500 ASSOCIATES DRIVE,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,500.00,08/01/2013,Cash or cash equivalent,207639429,XELJANZ,,Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug  CP 690 550  To Methotrexate  MTX  In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,11/25/2013,Cash or cash equivalent,207529640,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,11/21/2013,Cash or cash equivalent,207476728,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,380.00,08/09/2013,Cash or cash equivalent,207479358,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207483654,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,37.00,08/09/2013,Cash or cash equivalent,207540558,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,500.00,10/03/2013,Cash or cash equivalent,207487652,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,527.00,08/19/2013,Cash or cash equivalent,207552922,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,220.00,09/05/2013,Cash or cash equivalent,207476712,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,08/19/2013,Cash or cash equivalent,207480590,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207486862,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,12/19/2013,Cash or cash equivalent,207480304,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1733.75,12/19/2013,Cash or cash equivalent,207476836,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,450.00,10/03/2013,Cash or cash equivalent,207476734,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207497244,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,08/14/2013,In-kind items and services,207468388,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,08/19/2013,Cash or cash equivalent,207534180,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1733.75,11/21/2013,Cash or cash equivalent,207476742,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,09/27/2013,Cash or cash equivalent,207571806,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,09/27/2013,Cash or cash equivalent,207573828,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6699.80,11/26/2013,In-kind items and services,207491060,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,250.00,09/05/2013,Cash or cash equivalent,207476778,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207479440,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207458554,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2009.94,10/24/2013,In-kind items and services,207523566,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1500 ASSOCIATES DR,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2614.80,10/21/2013,Cash or cash equivalent,207662054,XELJANZ,,PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP690550 COMPARED TO METHOTREXATE IN METHOTREXATENAIVE PATIENTS WITH RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,76.00,08/19/2013,Cash or cash equivalent,207458166,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207459382,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207514888,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,772.20,08/28/2013,Cash or cash equivalent,207665944,,,,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,103.00,08/19/2013,Cash or cash equivalent,207460228,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 321,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6919.25,08/27/2013,Cash or cash equivalent,207514650,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,66.00,08/19/2013,Cash or cash equivalent,207460444,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207458880,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,589.00,08/19/2013,Cash or cash equivalent,207506373,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,718.00,08/19/2013,Cash or cash equivalent,207517294,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,718.00,08/19/2013,Cash or cash equivalent,207457652,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,11/25/2013,Cash or cash equivalent,207459478,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,08/09/2013,Cash or cash equivalent,207458364,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 W Ridgeway Ave,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6699.80,11/27/2013,In-kind items and services,207667641,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,49087.50,08/29/2013,In-kind items and services,207532792,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,Study Drug
Non-covered Recipient Entity,,,,,,,220 West Ridgeway Avenue,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,380.00,08/09/2013,Cash or cash equivalent,207493034,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,11/14/2013,In-kind items and services,207489344,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 321,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,191.75,11/26/2013,Cash or cash equivalent,207499206,TOVIAZ,,A 12WEEK RANDOMIZED OPENLABEL ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND greater than25 KG WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED W,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,09/13/2013,In-kind items and services,207482018,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ALL,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207548964,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,09/11/2013,Cash or cash equivalent,207581454,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,350.00,12/18/2013,Cash or cash equivalent,207481640,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,866.88,12/05/2013,Cash or cash equivalent,207563492,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,600.00,09/05/2013,Cash or cash equivalent,207518802,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207481666,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,513.00,09/27/2013,Cash or cash equivalent,207579708,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,125.00,09/05/2013,Cash or cash equivalent,207496762,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,08/19/2013,Cash or cash equivalent,207489950,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,600 Seventh Street SE,,CEDAR RAPIDS,52401,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,888.00,11/25/2013,Cash or cash equivalent,207542310,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,342.00,08/19/2013,Cash or cash equivalent,207532044,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,411.60,09/12/2013,Cash or cash equivalent,207651740,XELJANZ,,Long Term Effectiveness And Safety Of CP 690 550 For The Treatment Of Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 Pleasant St,,Des Moines,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2172.00,08/27/2013,In-kind items and services,207539944,ZYVOX,TYGACIL,LEADER program,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1265.00,10/03/2013,Cash or cash equivalent,207476772,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,205.00,08/19/2013,Cash or cash equivalent,207529710,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4995.00,11/06/2013,Cash or cash equivalent,200644674,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/27/2013,Cash or cash equivalent,200657002,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,500.00,12/11/2013,Cash or cash equivalent,200648098,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,65.31,08/29/2013,Cash or cash equivalent,200654057,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,13033.75,09/24/2013,Cash or cash equivalent,20388768,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,500.00,11/04/2013,Cash or cash equivalent,200638102,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,385.48,12/16/2013,Cash or cash equivalent,200657355,Victoza,,EX2211-3748,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,7313.00,11/06/2013,Cash or cash equivalent,200647388,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,4403.07,12/18/2013,Cash or cash equivalent,200636836,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,50.00,09/18/2013,Cash or cash equivalent,200655248,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,100.00,12/17/2013,Cash or cash equivalent,200637900,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,2048.00,10/15/2013,Cash or cash equivalent,200663756,Novoeight,,NN7008-3568,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,35.00,12/09/2013,Cash or cash equivalent,200647881,Victoza,,NN2211-4059,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,35.00,12/11/2013,Cash or cash equivalent,200644892,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1191.54,08/09/2013,Cash or cash equivalent,200652776,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,600.00,09/06/2013,Cash or cash equivalent,200654242,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/04/2013,Cash or cash equivalent,200653406,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,42.50,11/22/2013,Cash or cash equivalent,200653674,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,257.55,11/25/2013,Cash or cash equivalent,200638230,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,09/20/2013,Cash or cash equivalent,200653604,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4000.00,10/03/2013,Cash or cash equivalent,207520988,,,A DOUBLEBLIND  RANDOMIZED PLACEBOCONTROLLED PARALLEL DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3117.00,12/18/2013,Cash or cash equivalent,200636842,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,902.50,09/05/2013,Cash or cash equivalent,207514584,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF00547659 IN SUBJECTS WITH CROHNS DISEASE OPERA,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,9.90,11/15/2013,Cash or cash equivalent,200663968,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,73.45,08/01/2013,Cash or cash equivalent,200663970,Novoeight,,NN7008-3568,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,9697.50,11/07/2013,Cash or cash equivalent,200655656,Victoza,,EX2211-3748,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,8325.00,10/16/2013,Cash or cash equivalent,192847426,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,3826.83,08/09/2013,Cash or cash equivalent,192847450,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,75.00,08/29/2013,Cash or cash equivalent,200646768,Victoza,,NN2211-3659,,
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,5950.00,10/16/2013,Cash or cash equivalent,192847418,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1.65,11/19/2013,Cash or cash equivalent,200645076,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/10/2013,Cash or cash equivalent,200656718,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,412.97,12/03/2013,Cash or cash equivalent,200650084,Victoza,,NN2211-4059,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,1625.00,10/15/2013,Cash or cash equivalent,200663750,Novoeight,,NN7008-3568,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,14.94,12/19/2013,Cash or cash equivalent,200656278,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,20.00,12/20/2013,Cash or cash equivalent,200656904,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,770.96,12/26/2013,Cash or cash equivalent,200656786,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,3500.00,12/19/2013,Cash or cash equivalent,200665424,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,12032.00,09/02/2013,Cash or cash equivalent,20388767,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,20.82,08/15/2013,In-kind items and services,20388770,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,7756.56,12/13/2013,Cash or cash equivalent,20388773,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158-2946,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,1349.00,08/08/2013,Cash or cash equivalent,195567640,,,HYD3002,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,51.02,08/26/2013,In-kind items and services,25020708,KALYDECO,,STUDY OF IVACAFTOR IN CYSTIC FIBROSIS SUBJECTS AGED 12 YEARS AND OLDER WITH THE G551D MUTATION,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,44192.30,12/02/2013,Cash or cash equivalent,25019948,KALYDECO,,A STUDY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN CYSTIC FIBROSIS SUBJECTS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DELCFTR MUTATION TRANSPORT,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,29.64,08/15/2013,In-kind items and services,20388769,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,23.46,11/15/2013,In-kind items and services,20388775,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,250.00,12/23/2013,Cash or cash equivalent,195567792,,,HYD3003,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,4685.19,11/15/2013,In-kind items and services,20388776,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,50.00,12/09/2013,Cash or cash equivalent,195567380,,,HYD3002,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,3327.70,08/01/2013,Cash or cash equivalent,25019950,KALYDECO,,STUDY OF IVACAFTOR IN SUBJECTS WITH CYSTIC FIBROSIS WHO HAVE THE R117HCFTR MUTATION,,
Non-covered Recipient Entity,,,,,,,2800 PIERCE ST,STE 101,SIOUX CITY,51104,,,Allergan Inc.,100000000278,Allergan Inc.,CA,40.00,11/15/2013,Cash or cash equivalent,20388216,,,Breast Implant Follow-up Studies,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,57.37,12/09/2013,Cash or cash equivalent,195567384,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,18671.56,08/13/2013,Cash or cash equivalent,20388771,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158-2946,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,1299.00,09/19/2013,Cash or cash equivalent,195567642,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,3736.00,08/12/2013,Cash or cash equivalent,195567374,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,500.00,12/09/2013,Cash or cash equivalent,195567386,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,50.00,12/09/2013,Cash or cash equivalent,195567388,,,HYD3002,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,449.00,11/29/2013,In-kind items and services,25020654,KALYDECO,,A PHASE 3 ROLLOVER STUDY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS 12 YEARS AND OLDER WITH CYSTIC FIBROSIS,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,3625.70,12/13/2013,Cash or cash equivalent,20388772,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,4874.00,12/13/2013,Cash or cash equivalent,20388774,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,23.45,12/09/2013,Cash or cash equivalent,195567382,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1215 PLEASANT ST,STE 520,DES MOINES,50309,,,Allergan Inc.,100000000278,Allergan Inc.,CA,2995.62,12/02/2013,Cash or cash equivalent,20388777,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,2553.83,10/29/2013,In-kind items and services,25019871,KALYDECO,,STUDY OF VX809 ALONE AND IN COMBINATION WITH VX770 IN CYSTIC FIBROSIS CF PATIENTS HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DELCFTR MUTATION,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158-2946,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,203.00,09/19/2013,Cash or cash equivalent,195567922,,,HYD3003,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,500.00,12/23/2013,Cash or cash equivalent,195567790,,,HYD3003,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,5937.85,12/23/2013,Cash or cash equivalent,195567390,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,2875.75,09/16/2013,Cash or cash equivalent,195567376,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265-2623,,,Purdue Pharma L.P.,100000005432,Purdue Pharma L.P.,CT,357.00,10/15/2013,Cash or cash equivalent,195567378,,,HYD3002,,
Non-covered Recipient Entity,,,,,,,1500 ASSOCIATES DRIVE,,DUBUQUE,52002,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,312.00,11/20/2013,Cash or cash equivalent,207476428,XELJANZ,,PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP690550 COMPARED TO METHOTREXATE IN METHOTREXATENAIVE PATIENTS WITH RHEUMATOID ARTHRITIS,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,103.00,08/19/2013,Cash or cash equivalent,207460024,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,6699.80,12/02/2013,In-kind items and services,207470550,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,574,Central Iowa Hospital Corporation,,,,,1200 Pleasant St,,Des Moines,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2172.00,08/27/2013,In-kind items and services,207483628,ZYVOX,TYGACIL,LEADER program,,Study Drug
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,3645.00,08/22/2013,Cash or cash equivalent,7982691,YERVOY,,PhIII Prostate 2nd line CRPC   Ipi RT vs RT,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,1710.00,10/21/2013,Cash or cash equivalent,179785806,,,Prospective Research Assessment in Multiple Myeloma  An Observational Evaluation  PREAMBLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,13267.11,09/17/2013,Cash or cash equivalent,7983323,,,Phase III RCC Monotherapy vs. everolimus  ONO 4538 03,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,2439.40,10/23/2013,Cash or cash equivalent,7982681,YERVOY,,PhIII Prostate 2nd line CRPC   Ipi RT vs RT,,
Covered Recipient Teaching Hospital,573,Central Iowa Hospital Corporation,,,,,700 E University Ave,,Des Moines,50316,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,9100.00,10/28/2013,Cash or cash equivalent,179786590,NULOJIX,,Evaluating Nulojix Belatacept Long Term Safety in Transplant ENLIST,,
Covered Recipient Teaching Hospital,342,Mercy Health Services/Iowa Corp.,,,,,1000 4th St SW,SUITE IOPT,Mason City,50401,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,1500.00,08/22/2013,Cash or cash equivalent,7982453,SPRYCEL,,Studying Interventions for Managing Patients With Chronic Myeloid Leukemia  CML  in Chronic Phase  The 5 Year Prospective Cohort Study  SIMPLICITY,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,17121.50,10/17/2013,Cash or cash equivalent,179786609,,,Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed Previously Untreated Multiple Myeloma ELOQUENT   1,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,20405.30,09/19/2013,Cash or cash equivalent,7984569,NULOJIX,,Belatacept Evaluation of Nephroprotection and Efficacy as First line Immunosuppression Trial  BENEFIT,,
Covered Recipient Physician,,,1287740,RONALD,,JONES,345 BEAVER KREEK CTR,,NORTH LIBERTY,52317,Medical Doctor,Allopathic & Osteopathic Physicians|Pathology|Anatomic Pathology & Clinical Pathology,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,833.33,12/24/2013,Cash or cash equivalent,106217733,,,,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2102.40,12/10/2013,Cash or cash equivalent,31502768,BIO MMR RIT,,"A phase IIIA, randomized, observer blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals MMR vaccine 209762 Priorix  compared to Merck and Co., Inc. s MMR vaccine M M R II, as a first dose, both co administered with Varivax, Havrix and Prevnar 13 subset of children to healthy children 12 to 15 months of age.",,
Covered Recipient Physician,,,841636,SCOTT,,BROCK,1000 LANGWORTHY ST,,DUBUQUE,52001,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,150.00,12/10/2013,Cash or cash equivalent,31509897,SYNCRIA,,"A Randomized, Double blind, Placebo   and Active   Controlled, Parallel group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and with Metformin plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,698.76,12/18/2013,Cash or cash equivalent,31502767,VIANI,SERETIDE DISKUS,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1113.75,09/17/2013,Cash or cash equivalent,214916154,Proleukin,,PROCLAIM Registry,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,2560.50,12/17/2013,Cash or cash equivalent,214916130,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1265.63,12/17/2013,Cash or cash equivalent,214916148,Proleukin,,PROCLAIM Registry,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,4366.80,12/17/2013,Cash or cash equivalent,214916134,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,75.00,10/08/2013,Cash or cash equivalent,214916140,Proleukin,,A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,2812.50,11/19/2013,Cash or cash equivalent,214916138,Proleukin,,"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,8325.00,11/19/2013,Cash or cash equivalent,214916143,Proleukin,,"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Non-covered Recipient Entity,,,,,,,411 Laurel St Ste 3262,,Des Moines,50314,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,850.00,08/29/2013,Cash or cash equivalent,106164520,,,Ph IIb add on to LA insulin,,
Covered Recipient Physician,,,841636,SCOTT,,BROCK,1000 LANGWORTHY ST,,DUBUQUE,52001,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,115.00,12/04/2013,Cash or cash equivalent,31509895,SYNCRIA,,"A Randomized, Double Blind, Placebo  and Active Controlled, Parallel Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus",,
Covered Recipient Physician,,,260479,JENNIFER,,KAY,201 RIDGE ST,,COUNCIL BLFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,8222.04,09/16/2013,Cash or cash equivalent,31509529,VIANI,SERETIDE DISKUS,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1655.21,08/06/2013,Cash or cash equivalent,31503701,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3410.10,10/29/2013,Cash or cash equivalent,31502769,BIO MMR RIT,,"A phase IIIA, randomized, observer blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals MMR vaccine 209762 Priorix  compared to Merck and Co., Inc. s MMR vaccine M M R II, as a first dose, both co administered with Varivax, Havrix and Prevnar 13 subset of children to healthy children 12 to 15 months of age.",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,4498.73,09/24/2013,Cash or cash equivalent,31503700,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7.95,11/18/2013,Cash or cash equivalent,31045254,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1681.00,11/18/2013,Cash or cash equivalent,31043841,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,6718.50,12/09/2013,Cash or cash equivalent,31043467,Stivarga,,Bay73-4506 Regorafenib CRC EAP after failure of std therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7.95,11/18/2013,Cash or cash equivalent,31043760,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1320.88,11/22/2013,Cash or cash equivalent,31045903,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7.95,11/18/2013,Cash or cash equivalent,31043061,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,800.00,11/22/2013,Cash or cash equivalent,31044435,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1069.00,11/22/2013,Cash or cash equivalent,31043972,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1000.00,11/18/2013,Cash or cash equivalent,31045203,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2095.00,11/22/2013,Cash or cash equivalent,31044442,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1069.00,11/22/2013,Cash or cash equivalent,31046560,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7.95,11/18/2013,Cash or cash equivalent,31042865,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,330.22,11/22/2013,Cash or cash equivalent,31043158,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2109.38,10/25/2013,Cash or cash equivalent,31043894,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2138.00,12/11/2013,Cash or cash equivalent,31043925,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,736.00,11/18/2013,Cash or cash equivalent,31046319,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,800.00,11/22/2013,Cash or cash equivalent,31044576,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,800.00,11/22/2013,Cash or cash equivalent,31044187,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2290.00,11/18/2013,Cash or cash equivalent,31042947,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,800.00,11/22/2013,Cash or cash equivalent,31043139,Adempas,,BAY 63-2521 ph III CTEPH extension of 11348,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,4500.00,11/01/2013,Cash or cash equivalent,31042796,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7.95,11/18/2013,Cash or cash equivalent,31044411,Adempas,,BAY 63-2521 ph 3 EAS in CTEPH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DRIVE 1353 JCP,,Iowa City,52242,,,"Varian Medical Systems, Inc.",100000010850,"Varian Medical Systems, Inc.",CA,57865.00,09/17/2013,Cash or cash equivalent,106105159,,,A Portable Real-time HDR Applicator Monitoring System for Intracavitary Brachtherapy,,
Covered Recipient Physician,,,126578,Jerry,,Rozeboom,855 A Ave NE,Suite 200,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,"Intuitive Surgical Operations, Inc.",100000010533,"Intuitive Surgical Operations, Inc.",CA,5000.00,12/17/2013,Cash or cash equivalent,29585030,,,"Multicenter, Retrospective Evaluation of Robotic assisted Hysterectomy Outcomes",,
Covered Recipient Physician,,,126578,Jerry,,Rozeboom,855 A Ave NE,Suite 200,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,"Intuitive Surgical Operations, Inc.",100000010533,"Intuitive Surgical Operations, Inc.",CA,5000.00,12/26/2013,Cash or cash equivalent,29585032,,,"Multicenter, Retrospective Evaluation of Robotic assisted Hysterectomy Outcomes",,
Covered Recipient Physician,,,126578,Jerry,,Rozeboom,855 A Ave NE,Suite 200,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,"Intuitive Surgical Operations, Inc.",100000010533,"Intuitive Surgical Operations, Inc.",CA,5000.00,12/17/2013,Cash or cash equivalent,29585028,,,"Multicenter, Retrospective Evaluation of Robotic assisted Hysterectomy Outcomes",,
Non-covered Recipient Entity,,,,,,,1622 E. Lombard Street,,Davenport,52803,,,Bayer HealthCare LLC,100000005523,Medrad Inc.,PA,10276.88,09/03/2013,Cash or cash equivalent,31044850,,,Independent Study Support Bayer Product or TA,,
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,18750.00,10/11/2013,Cash or cash equivalent,31639983,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://www.clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,5375.00,11/13/2013,Cash or cash equivalent,31639984,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://www.clinicaltrials.gov/ct2/show/NCT01266265,NA
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1675.00,12/05/2013,Cash or cash equivalent,31639986,ORENITRAM,,AN OPEN-LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT,http://www.clinicaltrials.gov/ct2/show/NCT01027949,NA
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2475.75,12/02/2013,Cash or cash equivalent,31042957,Xofigo,,Open label non-comparative treatm of Alpharadin in CRPC pat,,
Covered Recipient Physician,,,1045914,SIF,,HANSDOTTIR,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,7312.50,11/27/2013,Cash or cash equivalent,31639985,TYVASO,,STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE,http://www.clinicaltrials.gov/ct2/show/NCT01266265,NA
Non-covered Recipient Entity,,,,,,,1 Edmundson Pl Ste 312,,Council Bluffs,51503,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,2043.36,12/04/2013,Cash or cash equivalent,29356571,Tiotropium-bromide,,TIOSPIR,,
Covered Recipient Teaching Hospital,582,State University of Iowa,,,,,200 HAWKINS DRIVE 1353 JCP,,Iowa City,52242,,,bioMerieux,100000000114,bioMerieux,NC,37737.50,12/10/2013,Cash or cash equivalent,216777054,,,VITEK 2,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,36.00,09/10/2013,Cash or cash equivalent,31326466,TIVICAY,,,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,495.25,08/01/2013,Cash or cash equivalent,29356381,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,420.00,11/14/2013,Cash or cash equivalent,30241679,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Non-covered Recipient Entity,,,,,,,PO Box 3014,,Ames,50010,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,3466.75,10/01/2013,Cash or cash equivalent,29357253,Dabigatran etexilate,,GLORIA-AF Registry Phase II-III  Core,,
Non-covered Recipient Entity,,,,,,,1500 Associates Dr,,Dubuque,52002,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,500.00,11/04/2013,Cash or cash equivalent,29357794,,,Ph III min. 52-wk extension trial,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1300.00,12/20/2013,Cash or cash equivalent,30242161,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,500.00,12/17/2013,Cash or cash equivalent,30242128,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,5000.00,12/05/2013,Cash or cash equivalent,30242160,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6TH AVE,,DES MOINES,50314,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1118.70,11/26/2013,Cash or cash equivalent,31326477,TIVICAY,,,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6TH AVE,,DES MOINES,50314,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1118.70,09/17/2013,Cash or cash equivalent,31326478,TIVICAY,,,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,3000.00,11/20/2013,Cash or cash equivalent,30242127,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,http://clinicaltrials.gov/ct2/show/NCT01841762?term=actelion+symphony&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,420.00,10/24/2013,Cash or cash equivalent,30241678,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1096.20,09/24/2013,Cash or cash equivalent,31326467,TIVICAY,,,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010476,"Actelion Pharmaceuticals, Ltd",CA,6187.50,08/06/2013,Cash or cash equivalent,30242050,TRACLEER BOSENTAN,,COMPASS 2 - AC-052-414 USA,http://clinicaltrials.gov/ct2/show/NCT00303459?term=actelion+compass+2&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010476,"Actelion Pharmaceuticals, Ltd",CA,4125.00,11/04/2013,Cash or cash equivalent,30242052,TRACLEER BOSENTAN,,COMPASS 2 - AC-052-414 USA,http://clinicaltrials.gov/ct2/show/NCT00303459?term=actelion+compass+2&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,3575.00,12/04/2013,In-kind items and services,30241682,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,284.08,12/31/2013,Cash or cash equivalent,30241684,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010476,"Actelion Pharmaceuticals, Ltd",CA,2062.50,10/28/2013,Cash or cash equivalent,30242051,TRACLEER BOSENTAN,,COMPASS 2 - AC-052-414 USA,http://clinicaltrials.gov/ct2/show/NCT00303459?term=actelion+compass+2&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,32252.25,12/02/2013,Cash or cash equivalent,106172774,Non-Covered Product,,Pre-Clinical_12 02 2013,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,4625.00,12/04/2013,Cash or cash equivalent,30241680,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,276.28,12/04/2013,Cash or cash equivalent,30241681,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,http://clinicaltrials.gov/ct2/show/NCT00667823?term=actelion+seraphin+ol&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,09/10/2013,Cash or cash equivalent,221398574,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1300.00,11/26/2013,Cash or cash equivalent,221411860,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221410980,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,11/13/2013,Cash or cash equivalent,221410988,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221411006,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,315.00,08/07/2013,Cash or cash equivalent,30241674,,,GRIPHON HQ - AC-065-302,http://clinicaltrials.gov/ct2/show/NCT01106014?term=actelion+griphon&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,09/10/2013,Cash or cash equivalent,221401432,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,09/10/2013,Cash or cash equivalent,221401434,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,09/10/2013,Cash or cash equivalent,221401442,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1300.00,09/18/2013,Cash or cash equivalent,30241676,,,GRIPHON OL HQ - AC-065-303,http://clinicaltrials.gov/ct2/show/NCT01112306?term=actelion+griphon&rank=2,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,779.72,12/31/2013,Cash or cash equivalent,30241683,,,GRIPHON HQ - AC-065-302,http://clinicaltrials.gov/ct2/show/NCT01106014?term=actelion+griphon&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,10/09/2013,Cash or cash equivalent,221405586,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,10/09/2013,Cash or cash equivalent,221405606,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,11/13/2013,Cash or cash equivalent,221411016,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221411024,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1300.00,09/18/2013,Cash or cash equivalent,30241675,,,GRIPHON HQ - AC-065-302,http://clinicaltrials.gov/ct2/show/NCT01106014?term=actelion+griphon&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,3360.00,10/10/2013,Cash or cash equivalent,30241677,,,GRIPHON HQ - AC-065-302,http://clinicaltrials.gov/ct2/show/NCT01106014?term=actelion+griphon&rank=1,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.87,08/13/2013,Cash or cash equivalent,221393880,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,08/13/2013,Cash or cash equivalent,221393882,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,08/13/2013,Cash or cash equivalent,221393884,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,12/10/2013,Cash or cash equivalent,221413288,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,11/27/2013,Cash or cash equivalent,220641388,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,09/19/2013,Cash or cash equivalent,220641400,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1500.00,09/13/2013,Cash or cash equivalent,220641212,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,11/22/2013,Cash or cash equivalent,220641516,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,09/19/2013,Cash or cash equivalent,220641530,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,08/13/2013,Cash or cash equivalent,221393862,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,08/13/2013,Cash or cash equivalent,221393870,,,BIOHELIX-I,,
Non-covered Recipient Entity,,,,,,,4405 Hamilton Boulevard,,Sioux City,51104,,,"Transcend Medical, Inc.",100000061364,"Transcend Medical, Inc.",CA,4000.00,10/11/2013,Cash or cash equivalent,221496005,,,COMPASS,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Par Pharmaceutical, Inc.",100000010989,"Par Pharmaceutical, Inc.",NY,13676.25,11/14/2013,Cash or cash equivalent,31746893,APLISOL,,"A Randomized, Double-blind Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative PPD Aplisol in Comparison with a Reference Standard Tuberculin Purified Protein Derivative PPD-S2 in Subjects Uninfected With M. tuberculosis or Other Mycobacteria",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Par Pharmaceutical, Inc.",100000010989,"Par Pharmaceutical, Inc.",NY,2126.25,11/08/2013,Cash or cash equivalent,31746892,APLISOL,,"A Randomized, Double-blind Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative PPD Aplisol in Comparison with a Reference Standard Tuberculin Purified Protein Derivative PPD-S2 in Subjects Uninfected With M. tuberculosis or Other Mycobacteria",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Par Pharmaceutical, Inc.",100000010989,"Par Pharmaceutical, Inc.",NY,13865.63,08/29/2013,Cash or cash equivalent,31746891,APLISOL,,"A Randomized, Double-blind Study to Demonstrate Equivalent Relative Specificity of Tuberculin Purified Protein Derivative PPD Aplisol in Comparison with a Reference Standard Tuberculin Purified Protein Derivative PPD-S2 for Detection of Tuberculosis in Subjects Infected With Atypical Mycobacteria",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,3969.00,12/17/2013,Cash or cash equivalent,221415258,,,SIELLO,,
Covered Recipient Physician,,,260479,JENNIFER,,KAY,201 RIDGE ST,,COUNCIL BLFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Family Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1653.33,10/28/2013,Cash or cash equivalent,31509531,VIANI,SERETIDE DISKUS,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH PERSISTENT ASTHMA,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,168.75,10/15/2013,Cash or cash equivalent,31502847,BIO HPV,,"A phase IIIb open label, multi centre immunization study to evaluate the safety of GlaxoSmithKline GSK Biologicals HPV 16 18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in female American and Canadian subjects who received the active control hepatitis A vaccine in the 580299 008 study.",,
Covered Recipient Physician,,,841636,SCOTT,,BROCK,1000 LANGWORTHY ST,,DUBUQUE,52001,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,115.00,12/04/2013,Cash or cash equivalent,31509896,SYNCRIA,,"A Randomized, Double Blind, Placebo  and Active Controlled, Parallel Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus",,
Covered Recipient Physician,,,841636,SCOTT,,BROCK,1000 LANGWORTHY ST,,DUBUQUE,52001,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,580.00,11/01/2013,Cash or cash equivalent,31509894,SYNCRIA,,"A Randomized, Open Label, Parallel Group, Multicenter Study to Determine the Efficacy and Long Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,West Des Moines,50266,,,"Salix Pharmaceuticals, Ltd",100000010796,"Salix Pharmaceuticals, Ltd",NC,10774.60,11/26/2013,Cash or cash equivalent,106161298,Solesta,,Long Term Safety and Efficacy of Solesta Injectable Bulking Agent for the Treatment of Fecal Incontinence,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,243.75,08/20/2013,Cash or cash equivalent,31509162,VOTRIENT,,"A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221410992,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221410994,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,11/13/2013,Cash or cash equivalent,221410996,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221411004,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,09/10/2013,Cash or cash equivalent,221401422,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,09/10/2013,Cash or cash equivalent,221401426,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,167.99,11/13/2013,Cash or cash equivalent,221407572,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.87,11/13/2013,Cash or cash equivalent,221407576,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,09/10/2013,Cash or cash equivalent,221401440,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/10/2013,Cash or cash equivalent,221413298,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221410970,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221410982,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,11/13/2013,Cash or cash equivalent,221410986,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,11/13/2013,Cash or cash equivalent,221411002,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,10/09/2013,Cash or cash equivalent,221405578,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,10/09/2013,Cash or cash equivalent,221405584,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,10/09/2013,Cash or cash equivalent,221405598,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,10/09/2013,Cash or cash equivalent,221405612,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,08/13/2013,Cash or cash equivalent,221393876,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,11/13/2013,Cash or cash equivalent,221411028,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,11/13/2013,Cash or cash equivalent,221411032,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,11/13/2013,Cash or cash equivalent,221411034,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,09/10/2013,Cash or cash equivalent,221401412,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,09/10/2013,Cash or cash equivalent,221401424,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,09/10/2013,Cash or cash equivalent,221401436,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,08/13/2013,Cash or cash equivalent,221393868,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,12/10/2013,Cash or cash equivalent,221413284,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/10/2013,Cash or cash equivalent,221413290,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,12/10/2013,Cash or cash equivalent,221413296,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,12/10/2013,Cash or cash equivalent,221413300,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221410974,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,11/13/2013,Cash or cash equivalent,221410978,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,09/10/2013,Cash or cash equivalent,221398570,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,09/10/2013,Cash or cash equivalent,221398572,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,11/13/2013,Cash or cash equivalent,221410990,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,10/09/2013,Cash or cash equivalent,221405602,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,08/13/2013,Cash or cash equivalent,221393886,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.87,11/13/2013,Cash or cash equivalent,221407578,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,11/13/2013,Cash or cash equivalent,221411026,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,11/13/2013,Cash or cash equivalent,221411030,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,09/10/2013,Cash or cash equivalent,221401414,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,08/13/2013,Cash or cash equivalent,221393878,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,10/09/2013,Cash or cash equivalent,221405590,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,10/09/2013,Cash or cash equivalent,221405604,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,09/10/2013,Cash or cash equivalent,221401410,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,08/13/2013,Cash or cash equivalent,221393866,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,08/13/2013,Cash or cash equivalent,221393864,,,BIOHELIX-I,,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,920.00,11/01/2013,Cash or cash equivalent,216029922,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/10/2013,Cash or cash equivalent,221413286,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/10/2013,Cash or cash equivalent,221413294,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,12/10/2013,Cash or cash equivalent,221413302,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,11/13/2013,Cash or cash equivalent,221407570,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,11/13/2013,Cash or cash equivalent,221407580,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221410976,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221410998,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,11/13/2013,Cash or cash equivalent,221411008,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,11/13/2013,Cash or cash equivalent,221407582,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,11/13/2013,Cash or cash equivalent,221407590,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,10/09/2013,Cash or cash equivalent,221405596,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,10/09/2013,Cash or cash equivalent,221405614,,,ProMRI,,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,277.20,09/13/2013,Cash or cash equivalent,216029540,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,1120.00,09/06/2013,Cash or cash equivalent,216029470,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,09/10/2013,Cash or cash equivalent,221401418,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,09/10/2013,Cash or cash equivalent,221401438,,,ProMRI,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242,,,Zimmer Holding Inc,100000000103,Zimmer Holding Inc,IN,12000.00,12/19/2013,Cash or cash equivalent,105896167,,,104604 Hip Research Study,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,09/10/2013,Cash or cash equivalent,221401428,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,09/10/2013,Cash or cash equivalent,221401430,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,11/13/2013,Cash or cash equivalent,221407586,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,11/13/2013,Cash or cash equivalent,221407588,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,08/13/2013,Cash or cash equivalent,221393874,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,11/13/2013,Cash or cash equivalent,221407594,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,634.21,12/10/2013,Cash or cash equivalent,221413292,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,11/13/2013,Cash or cash equivalent,221410984,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221411000,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,11/13/2013,Cash or cash equivalent,221411038,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,10/09/2013,Cash or cash equivalent,221405592,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,10/09/2013,Cash or cash equivalent,221405600,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,10/09/2013,Cash or cash equivalent,221405608,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,10/09/2013,Cash or cash equivalent,221405610,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,11/13/2013,Cash or cash equivalent,221407574,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,11/13/2013,Cash or cash equivalent,221407584,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,11/13/2013,Cash or cash equivalent,221407592,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1892.88,11/13/2013,Cash or cash equivalent,221411010,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,11/13/2013,Cash or cash equivalent,221411014,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221411022,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,11/13/2013,Cash or cash equivalent,221410966,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221410968,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,11/13/2013,Cash or cash equivalent,221410972,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,10/09/2013,Cash or cash equivalent,221405580,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,10/09/2013,Cash or cash equivalent,221405582,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,10/09/2013,Cash or cash equivalent,221405588,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,09/10/2013,Cash or cash equivalent,221401416,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,09/10/2013,Cash or cash equivalent,221401420,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,09/10/2013,Cash or cash equivalent,221401444,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,11/13/2013,Cash or cash equivalent,221411012,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,11/13/2013,Cash or cash equivalent,221411018,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,11/13/2013,Cash or cash equivalent,221411020,,,ProMRI,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,275.74,08/13/2013,Cash or cash equivalent,221393872,,,BIOHELIX-I,,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,464.40,12/19/2013,In-kind items and services,24487569,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,ATTN ANUJ BHARGAVA,411 LAUREL STREET SUITE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,6192.00,09/25/2013,Cash or cash equivalent,24459393,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET SUITE 3262,,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3075.00,10/28/2013,Cash or cash equivalent,24483712,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Physician,,,708876,TIMOTHY,,STAUDTE,5409 AVENUE O STE 1,,FORT MADISON,52627,Doctor of Osteopathy,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,100.00,12/10/2013,Cash or cash equivalent,24474412,IMPLANON,,Post authorization safety study IMPLANON NXT observational cohort study,,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,225.60,08/13/2013,In-kind items and services,24490089,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,20342.20,12/27/2013,Cash or cash equivalent,24457500,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,10143.40,10/25/2013,Cash or cash equivalent,24453530,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,250.00,09/18/2013,Cash or cash equivalent,24472870,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,628.00,11/18/2013,Cash or cash equivalent,24478963,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET SUITE 3262,,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3648.00,12/11/2013,Cash or cash equivalent,24478421,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,309.60,08/13/2013,In-kind items and services,24490091,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,315.00,11/21/2013,Cash or cash equivalent,24456251,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,207.99,10/02/2013,Cash or cash equivalent,24483601,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,464.40,11/11/2013,In-kind items and services,24487568,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,207.98,11/25/2013,Cash or cash equivalent,24478931,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,4075.00,09/18/2013,Cash or cash equivalent,24466858,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Physician,,,637065,EVA,,TSALIKIAN,B5 Jessup Hall,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,496.60,11/06/2013,In-kind items and services,24484181,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,154.80,09/26/2013,In-kind items and services,24490087,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Physician,,,256009,WILLIAM,PATRICK,FUSSELMAN,202 10th St SSuite 165,,Cedar Rapids,52403,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,81.48,10/11/2013,In-kind items and services,24490853,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,855 A Avenue NE,Suite 420,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,81.60,10/30/2013,In-kind items and services,24481112,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Physician,,,256009,WILLIAM,PATRICK,FUSSELMAN,202 10th St SSuite 165,,Cedar Rapids,52403,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,429.10,11/11/2013,In-kind items and services,24490852,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,Suite 420,,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,81.60,11/25/2013,In-kind items and services,24481114,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Non-covered Recipient Entity,,,,,,,RESEARCH MANAGER,5880 UNIVERSITY,WEST DES MOINES,50266,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,6500.00,08/19/2013,Cash or cash equivalent,24460800,VYTORIN,,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin EzetimibeSimvastatin Tablet vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,200 Hawkins Drive,General Hospital,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,75.84,11/11/2013,In-kind items and services,24486511,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,Suite 420,,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,13.60,10/30/2013,In-kind items and services,24481191,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Physician,,,256009,WILLIAM,PATRICK,FUSSELMAN,202 10th St SSuite 165,,Cedar Rapids,52403,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,85.82,10/11/2013,In-kind items and services,24490884,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,General Hospital,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,122.60,11/11/2013,In-kind items and services,24486800,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,200 Hawkins Drive,General Hospital,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,49.04,11/11/2013,In-kind items and services,24486832,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,225.60,09/26/2013,In-kind items and services,24490090,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,855 A Avenue NE,Suite 420,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,81.60,11/25/2013,In-kind items and services,24481115,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,112.80,09/26/2013,In-kind items and services,24490048,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,103.99,10/02/2013,Cash or cash equivalent,24483600,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,420.00,11/21/2013,Cash or cash equivalent,24456218,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3662.00,11/04/2013,Cash or cash equivalent,24478934,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,240.00,11/13/2013,Cash or cash equivalent,24478933,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Physician,,,211123,ANUJ,,BHARGAVA,305 31st Street,,WEST DES MOINES,50265,Medical Doctor,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,377.59,12/20/2013,In-kind items and services,24448863,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Physician,,,211123,ANUJ,,BHARGAVA,305 31st Street,,WEST DES MOINES,50265,Medical Doctor,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,395.46,08/09/2013,In-kind items and services,24446207,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,103.99,08/21/2013,Cash or cash equivalent,24463942,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Physician,,,211123,ANUJ,,BHARGAVA,305 31st Street,,WEST DES MOINES,50265,Medical Doctor,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,577.36,10/04/2013,In-kind items and services,24448900,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3500.00,11/14/2013,Cash or cash equivalent,24482320,VYTORIN,,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin EzetimibeSimvastatin Tablet vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,640.00,11/25/2013,Cash or cash equivalent,24478964,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1256.00,12/18/2013,Cash or cash equivalent,24476097,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Physician,,,708876,TIMOTHY,,STAUDTE,5409 AVENUE O STE 1,,FORT MADISON,52627,Doctor of Osteopathy,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,300.00,11/01/2013,Cash or cash equivalent,24479911,IMPLANON,,Post authorization safety study IMPLANON NXT observational cohort study,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,9000.00,11/19/2013,Cash or cash equivalent,24482321,VYTORIN,,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin EzetimibeSimvastatin Tablet vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2500.00,12/11/2013,Cash or cash equivalent,24484845,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,103.99,08/21/2013,Cash or cash equivalent,24466769,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,General Hospital,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,61.30,11/11/2013,In-kind items and services,24486833,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,300.00,10/28/2013,Cash or cash equivalent,24453561,NOXAFIL,,"Phase IB study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1500.00,09/18/2013,Cash or cash equivalent,24462602,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,315.00,11/21/2013,Cash or cash equivalent,24456252,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,General Hospital,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,122.60,11/11/2013,In-kind items and services,24486799,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,13588.00,12/23/2013,Cash or cash equivalent,24476098,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,17864.60,10/01/2013,Cash or cash equivalent,24453560,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,207.99,11/13/2013,Cash or cash equivalent,24478932,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone FuroateFormoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Ado",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,400.00,09/12/2013,Cash or cash equivalent,24450831,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,15938.40,08/22/2013,Cash or cash equivalent,24451389,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Physician,,,708876,TIMOTHY,,STAUDTE,5409 AVENUE O STE 1,,FORT MADISON,52627,Doctor of Osteopathy,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,100.00,10/03/2013,Cash or cash equivalent,24479910,IMPLANON,,Post authorization safety study IMPLANON NXT observational cohort study,,
Non-covered Recipient Entity,,,,,,,ATTN ANUJ BHARGAVA,411 LAUREL STREET SUITE 3262,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3827.00,08/16/2013,Cash or cash equivalent,24460797,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,200 Hawkins Drive,General Hospital,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,122.60,11/11/2013,In-kind items and services,24486831,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Physician,,,211123,ANUJ,,BHARGAVA,305 31st Street,,WEST DES MOINES,50265,Medical Doctor,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,265.00,11/14/2013,In-kind items and services,24448862,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,General Hospital,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,89.30,11/11/2013,In-kind items and services,24486512,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET SUITE 3262,,DES MOINES,50314,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,5275.00,11/27/2013,Cash or cash equivalent,24482319,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Physician,,,765266,GERALD,H,CLAMON,General Hospital,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,89.30,11/11/2013,In-kind items and services,24486303,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Physician,,,211123,ANUJ,,BHARGAVA,305 31st Street,,WEST DES MOINES,50265,Medical Doctor,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,182.52,09/11/2013,In-kind items and services,24446206,JANUVIA,,"TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,14500.00,11/21/2013,Cash or cash equivalent,24456249,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,547.20,09/13/2013,In-kind items and services,24490092,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,Suite 420,,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,48.47,10/30/2013,In-kind items and services,24481193,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3550.00,09/16/2013,Cash or cash equivalent,24462678,VYTORIN,,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin EzetimibeSimvastatin Tablet vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac",,
Covered Recipient Physician,,,806076,MOHAMMED,MAHMOUD,MILHEM,JESSUP HALL,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,182.40,09/26/2013,In-kind items and services,24490088,MK-3475,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,3385.20,12/27/2013,Cash or cash equivalent,24457501,V503,,"A Randomized, International, Double-Blinded With In-House Blinding, Controlled With GARDASILTM, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus",,
Covered Recipient Physician,,,708876,TIMOTHY,,STAUDTE,5409 AVENUE O STE 1,,FORT MADISON,52627,Doctor of Osteopathy,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,100.00,08/02/2013,Cash or cash equivalent,24469709,IMPLANON,,Post authorization safety study IMPLANON NXT observational cohort study,,
Covered Recipient Physician,,,404245,TAHER,BASHIR,ABU HEJLEH,200 Hawkins Drive,,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,259.04,10/10/2013,In-kind items and services,24483824,MK-3475,,A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,Suite 420,,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,13.60,10/30/2013,In-kind items and services,24481192,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Non-covered Recipient Entity,,,,,,,RESEARCH MANAGER,5880 UNIVERSITY,WEST DES MOINES,50266,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,4900.00,12/11/2013,Cash or cash equivalent,24478448,VYTORIN,,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin EzetimibeSimvastatin Tablet vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac",,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,855 A Avenue NE,Suite 420,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,81.60,11/25/2013,In-kind items and services,24481113,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1500.00,11/21/2013,Cash or cash equivalent,24456250,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in",,
Covered Recipient Physician,,,1171097,DAVID,WILLIAM,ZENK,Suite 420,,Cedar Rapids,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,73.50,11/25/2013,In-kind items and services,24481111,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,11849.60,10/22/2013,Cash or cash equivalent,24453559,V503,,"A Randomized, International, Double-Blinded With In-House Blinding, Controlled With GARDASILTM, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus",,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,33172.34,08/01/2013,In-kind items and services,23929586,UTIBRON,,LOW DOSE STUDY 1 OF QVA VS  ADVAIR FOR TREATMENT OF COPD,,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,160.00,12/20/2013,Cash or cash equivalent,216030820,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,2052.00,08/09/2013,Cash or cash equivalent,216029272,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Siemens Medical Solutions USA, Inc.",100000010755,"Siemens Medical Solutions USA, Inc.",PA,32589.00,12/31/2013,Cash or cash equivalent,216839166,,,Functional Lung Imaging with Dual energy CT,,
Covered Recipient Teaching Hospital,572,CATHOLIC HEALTH INITIATIVES IOWA CORP,,,,,1111 6TH AVE,,DES MOINES,50314,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1260.45,08/21/2013,Cash or cash equivalent,23928745,ENTRESTO,,A MULTI CENTER  RANDOMIZED  DOUBLE BLIND  PARALLEL GROUP  ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY  AND SAFETY OF LCZ696 COMPARED TO ENALAPRIL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION,,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,40.00,11/15/2013,Cash or cash equivalent,216030408,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,14540.40,11/01/2013,Cash or cash equivalent,216029920,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,5961.10,09/06/2013,Cash or cash equivalent,216029392,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,Grant Accounting Office,,Iowa City,52242,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,980.00,09/13/2013,Cash or cash equivalent,30789005,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (?16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,19324.60,09/06/2013,Cash or cash equivalent,216029472,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,10000.00,09/13/2013,Cash or cash equivalent,216029498,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Non-covered Recipient Entity,,,,,,,1235 EIGHTH ST,,WEST DES MOINES,50265,,,"BioDelivery Sciences International, Inc.",100000061387,"BioDelivery Sciences International, Inc.",NC,357.30,11/15/2013,Cash or cash equivalent,216030410,,,"A PHASE 3, STUDY TO EVALUATE THE ANALGESIC EFFICACY, SAFETY, AND TOLERABILITY OF BEMA BUPRENORPHINE IN OPIOID EXPERIENCED SUBJECTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN",,
Covered Recipient Physician,,,34420,LYNN,K,STRUCK,1221 PLEASANT ST,SUITE 300,DES MOINES,50309-1423,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,24843.60,09/13/2013,Cash or cash equivalent,106195103,Neupro,,A multi-center multinational double blind placebo controlled three arm Phase 4 study to evaluate the efficacy of Rotigotine on Parkinsons disease associated apathy motor symptoms and mood,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,52602.16,08/01/2013,In-kind items and services,23929588,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Covered Recipient Teaching Hospital,583,BROADLAWNS MEDICAL CENTER,,,,,1801 HICKMAN ROAD,,DES MOINES,50314,,,UCB Biosciences Inc.,100000010780,UCB Biosciences Inc.,NC,14110.00,11/13/2013,Cash or cash equivalent,190033502,Vimpat,,"A Multi-center, Open-label, Trial to Assess the Efficacy of Lacosamide as First Add-on Treatment in Subjects with Partial-onset Seizures (FILAE)",,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,5.40,11/04/2013,Cash or cash equivalent,200658298,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,202.50,10/30/2013,Cash or cash equivalent,200661838,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Dr,,Iowa City,52242,,,NOVARTIS PHARMACEUTICALS CORPORATION,100000000228,NOVARTIS PHARMACEUTICALS CORPORATION,NJ,3000.00,11/11/2013,Cash or cash equivalent,227641846,SEEBRI,,A 12 WEEK MULTI CENTER  RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NVA237 IN STABLE COPD PATIENTS,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,51.24,12/04/2013,Cash or cash equivalent,200658010,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,912.38,10/29/2013,Cash or cash equivalent,200660160,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,628.52,09/30/2013,Cash or cash equivalent,310861618,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,252.00,08/01/2013,In-kind items and services,310861622,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,252.00,10/09/2013,In-kind items and services,310861630,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,252.00,12/05/2013,In-kind items and services,310861638,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,08/27/2013,In-kind items and services,310861646,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,105.00,09/19/2013,In-kind items and services,310861654,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,84.00,12/05/2013,In-kind items and services,310861660,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,08/27/2013,In-kind items and services,310861666,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,10/08/2013,In-kind items and services,310861672,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,11/05/2013,In-kind items and services,310861678,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,11/07/2013,In-kind items and services,310861684,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,12/17/2013,In-kind items and services,310861699,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,08/20/2013,In-kind items and services,310861704,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,08/27/2013,In-kind items and services,310861708,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,65124.93,08/01/2013,In-kind items and services,23929584,SEEBRI,,A MULTI CENTER  RANDOMIZED  DOUBLE BLIND  52 WEEK STUDY TO ASSESS THE SAFETY OF NVA237 COMPARED TO QAB149 IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE  COPD  WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,09/26/2013,In-kind items and services,310861712,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,11/05/2013,In-kind items and services,310861718,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,11/05/2013,In-kind items and services,310861728,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,09/26/2013,In-kind items and services,310861736,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,11/05/2013,In-kind items and services,310861740,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,42.00,10/08/2013,In-kind items and services,310861744,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,42.00,12/17/2013,In-kind items and services,310861752,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8.00,08/20/2013,In-kind items and services,310861760,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8.00,11/07/2013,In-kind items and services,310861765,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8.00,11/14/2013,In-kind items and services,310861768,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,281.70,08/01/2013,In-kind items and services,310861776,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,38059.72,08/01/2013,In-kind items and services,23929585,SEEBRI,,A MULTI CENTER  RANDOMIZED  DOUBLE BLIND  52 WEEK STUDY TO ASSESS THE SAFETY OF NVA237 COMPARED TO QAB149 IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE  COPD  WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,67573.20,08/01/2013,In-kind items and services,23929589,UTIBRON,,A 12 WEEK TREATMENT  MULTI CENTER  RANDOMIZED  DOUBLE BLIND  PARALLEL GROUP  PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY  SAFETY AND TOLERABILITY OF QVA149  INDACATEROL MALEATE GLYCOPYRRONIUM BROMIDE  IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.95,08/23/2013,In-kind items and services,310861780,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,21.57,09/25/2013,In-kind items and services,310861787,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,143.55,10/29/2013,In-kind items and services,310861796,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,28.76,12/16/2013,In-kind items and services,310861804,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,395.00,10/28/2013,In-kind items and services,310861812,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,45.83,12/01/2013,In-kind items and services,310861820,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,45.83,11/01/2013,In-kind items and services,310861826,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,45.83,10/01/2013,In-kind items and services,310861836,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,210 E IOWA AVE,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,33170.83,08/01/2013,In-kind items and services,23931706,SEEBRI,,A 12 WEEK MULTI CENTER  RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NVA237 IN STABLE COPD PATIENTS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,FL 2,AMES,50010-5400,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,17633.26,08/01/2013,In-kind items and services,23930507,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,236040.00,08/01/2013,In-kind items and services,23929583,SEEBRI,,A 12 WEEK MULTI CENTER  RANDOMIZED  DOUBLE BLIND  PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NVA237 IN STABLE COPD PATIENTS,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702-5014,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1921.00,11/22/2013,Cash or cash equivalent,23930802,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,51252.46,08/01/2013,In-kind items and services,23929590,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702-5014,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,11785.44,10/01/2013,In-kind items and services,23930801,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,225 E BURLINGTON ST,,IOWA CITY,52240,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,21738.08,08/05/2013,Cash or cash equivalent,154493226,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,97297.00,08/01/2013,In-kind items and services,23929587,UTIBRON,,A 12 WEEK TREATMENT  MULTI CENTER  RANDOMIZED  DOUBLE BLIND  PARALLEL GROUP  PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY  SAFETY AND TOLERABILITY OF QVA149  INDACATEROL MALEATE GLYCOPYRRONIUM BROMIDE  IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,225 E BURLINGTON ST,,IOWA CITY,52240,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,182390.97,08/01/2013,In-kind items and services,154493220,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,STE 201,COUNCIL BLUFFS,51503-4662,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,48672.48,08/01/2013,In-kind items and services,154490688,SEEBRI,,A 12 WEEK MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NVA237 IN STABLE COPD PATIENTS,,
Non-covered Recipient Entity,,,,,,,225 BURLINGTON ST W,,IOWA CITY,52242-1523,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,4409.00,08/01/2013,In-kind items and services,154493230,UTIBRON,,LOW DOSE STUDY 2 OF QVA VS ADVAIR FOR TREATMENT OF COPD,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,195.00,10/28/2013,In-kind items and services,311287324,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,395.00,10/28/2013,In-kind items and services,311287338,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,245.00,12/16/2013,In-kind items and services,311287352,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1300.00,11/21/2013,In-kind items and services,311338251,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,E 257 GH,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1560.00,11/11/2013,In-kind items and services,311338268,Repatha,,OSLER2 Ph3 OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,E 257 GH,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2160.00,12/11/2013,In-kind items and services,311338278,Repatha,,OSLER2 Ph3 OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE,E 257 GH,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2160.00,10/15/2013,In-kind items and services,311338286,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,11/21/2013,In-kind items and services,311338292,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,420.00,11/21/2013,In-kind items and services,311338297,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,12/16/2013,In-kind items and services,311338306,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,12/16/2013,In-kind items and services,311338317,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1300.00,08/27/2013,In-kind items and services,311338325,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,12/24/2013,In-kind items and services,311338334,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,12/24/2013,In-kind items and services,311338342,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1000.00,12/24/2013,In-kind items and services,311338354,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,390.00,12/24/2013,In-kind items and services,311338368,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1300.00,11/20/2013,In-kind items and services,311338380,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,11/20/2013,In-kind items and services,311338390,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,480.00,09/23/2013,In-kind items and services,311338394,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,480.00,09/30/2013,In-kind items and services,311338403,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,480.00,11/04/2013,In-kind items and services,311338411,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,480.00,12/02/2013,In-kind items and services,311338418,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,378.00,10/01/2013,In-kind items and services,311338434,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,315.00,08/01/2013,In-kind items and services,311338446,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,08/27/2013,In-kind items and services,311338462,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,11/07/2013,In-kind items and services,311338469,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,12/05/2013,In-kind items and services,311338476,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,105.00,09/19/2013,In-kind items and services,311338486,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,11/19/2013,In-kind items and services,311338494,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,12/05/2013,In-kind items and services,311338504,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,08/06/2013,In-kind items and services,311338514,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,10/09/2013,In-kind items and services,311338524,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,84.00,12/05/2013,In-kind items and services,311338530,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,08/01/2013,In-kind items and services,311338537,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,08/27/2013,In-kind items and services,311338550,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,11/19/2013,In-kind items and services,311338554,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,12/05/2013,In-kind items and services,311338564,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,16.00,11/14/2013,In-kind items and services,311338568,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8.00,08/01/2013,In-kind items and services,311338578,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8.00,12/05/2013,In-kind items and services,311338584,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/08/2013,In-kind items and services,311338593,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/08/2013,In-kind items and services,311338598,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.35,10/08/2013,In-kind items and services,311338608,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,10/08/2013,In-kind items and services,311338616,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,10/08/2013,In-kind items and services,311338626,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10.97,10/20/2013,In-kind items and services,311338630,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,12/15/2013,In-kind items and services,311338646,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,12/15/2013,In-kind items and services,311338660,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,12/15/2013,In-kind items and services,311338670,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19.45,12/15/2013,In-kind items and services,311338678,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,12/15/2013,In-kind items and services,311338694,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,12/15/2013,In-kind items and services,311338708,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.50,12/15/2013,In-kind items and services,311338716,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338730,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338743,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338754,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338762,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338774,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338784,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,0.70,12/15/2013,In-kind items and services,311338795,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,90.00,10/23/2013,In-kind items and services,311338804,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,82.10,09/04/2013,In-kind items and services,311338812,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,14.38,10/11/2013,In-kind items and services,311338825,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,133.97,10/16/2013,In-kind items and services,311338836,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,80.01,11/19/2013,In-kind items and services,311338852,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,55.43,12/11/2013,In-kind items and services,311338862,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,83.03,09/05/2013,In-kind items and services,311338870,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,98.32,09/10/2013,In-kind items and services,311338880,Repatha,,LAPLACE2 Combination Therapy,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,18.58,09/09/2013,In-kind items and services,311338890,Repatha,,OSLER2 Ph3 OLE,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,194.80,11/04/2013,In-kind items and services,311338902,Repatha,,OSLER2 Ph3 OLE,,
Non-covered Recipient Entity,,,,,,,"2055 KIMBALL AVE, STE 101",,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,5117.02,09/30/2013,Cash or cash equivalent,311286879,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,252.00,08/01/2013,In-kind items and services,311286899,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,252.00,10/09/2013,In-kind items and services,311286913,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,252.00,12/04/2013,In-kind items and services,311286929,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,189.00,09/05/2013,In-kind items and services,311286942,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,150.00,11/18/2013,In-kind items and services,311286956,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,08/27/2013,In-kind items and services,311286964,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,11/26/2013,In-kind items and services,311286978,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,11/26/2013,In-kind items and services,311286992,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,126.00,12/05/2013,In-kind items and services,311287006,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,09/24/2013,In-kind items and services,311287020,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,12/18/2013,In-kind items and services,311287036,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,100.00,08/29/2013,In-kind items and services,311287054,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,84.00,09/19/2013,In-kind items and services,311287070,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,84.00,12/04/2013,In-kind items and services,311287080,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,12/12/2013,In-kind items and services,311287098,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,63.00,09/24/2013,In-kind items and services,311287106,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,10/04/2013,In-kind items and services,311287122,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,12/05/2013,In-kind items and services,311287142,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,12/05/2013,In-kind items and services,311287156,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2250.00,08/08/2013,Cash or cash equivalent,311338114,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1365.00,10/08/2013,Cash or cash equivalent,311338130,Repatha,,OSLER OLE,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,50.00,11/18/2013,In-kind items and services,311287171,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,42.00,09/24/2013,In-kind items and services,311287186,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,42.00,12/05/2013,In-kind items and services,311287200,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,16.00,11/14/2013,In-kind items and services,311287224,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8.00,08/13/2013,In-kind items and services,311287238,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,35.95,08/21/2013,In-kind items and services,311287253,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,61.45,09/06/2013,In-kind items and services,311287264,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,106.68,09/25/2013,In-kind items and services,311287280,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,61.16,10/03/2013,In-kind items and services,311287293,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,71.90,11/06/2013,In-kind items and services,311287308,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,12336.40,10/08/2013,Cash or cash equivalent,311338140,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,601.80,10/24/2013,Cash or cash equivalent,311338154,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2375.00,11/12/2013,Cash or cash equivalent,311338166,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,54502.50,11/13/2013,Cash or cash equivalent,311338177,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3198.00,11/13/2013,Cash or cash equivalent,311338188,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,10031.25,11/22/2013,Cash or cash equivalent,311338199,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1000.00,11/21/2013,Cash or cash equivalent,311338208,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3218.75,12/16/2013,Cash or cash equivalent,311338214,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1240.00,12/16/2013,Cash or cash equivalent,311338227,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2007.00,12/16/2013,Cash or cash equivalent,311338240,Repatha,,LAPLACE2 Combination Therapy,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26838.00,12/03/2013,In-kind items and services,327151108,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5269.53,09/27/2013,In-kind items and services,327151118,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2258.37,08/07/2013,In-kind items and services,327150906,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,220 W Ridgeway Ave,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7527.90,10/25/2013,In-kind items and services,327151414,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3763.95,10/17/2013,In-kind items and services,327150422,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3011.16,10/23/2013,In-kind items and services,327149658,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35784.00,08/05/2013,In-kind items and services,327151242,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2258.37,08/07/2013,In-kind items and services,327150230,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,582,STATE UNIVERSITY OF IOWA,,,,,C-O GRANT ACCOUNTING OFFICE,B5 JESSUP HALL,IOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,9565.00,10/29/2013,Cash or cash equivalent,116152394,Letairis,,"ABS-LT: Ambrisentan in Pulmonary Hypertension: A Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects with Pulmonary Hypertension",,GS-US-300-0124
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2258.37,11/08/2013,In-kind items and services,327150798,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,8500.00,08/28/2013,Cash or cash equivalent,311115338,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2677.50,10/11/2013,Cash or cash equivalent,311115350,IMLYGIC,,OPTiM P3 Melanoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,24999.00,11/01/2013,Cash or cash equivalent,311115357,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,19893.00,11/26/2013,Cash or cash equivalent,311115364,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2400.00,08/27/2013,In-kind items and services,311115376,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3200.00,09/10/2013,In-kind items and services,311115390,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,4000.00,08/12/2013,In-kind items and services,311115401,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,5600.00,09/23/2013,In-kind items and services,311115414,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,400.00,09/10/2013,In-kind items and services,311115418,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,31.76,11/18/2013,In-kind items and services,311115428,IMLYGIC,,OPTiM P3 Melanoma,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,183.78,08/16/2013,In-kind items and services,311115440,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,22.05,08/16/2013,In-kind items and services,311115444,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,66.24,09/18/2013,In-kind items and services,311115462,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,183.78,08/23/2013,In-kind items and services,311115474,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,245.04,09/07/2013,In-kind items and services,311115479,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,97.32,08/23/2013,In-kind items and services,311115489,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,64.88,09/07/2013,In-kind items and services,311115502,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,61.26,11/14/2013,In-kind items and services,311115515,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,214.41,11/14/2013,In-kind items and services,311115528,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,30.00,08/16/2013,In-kind items and services,311115557,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,30.00,09/10/2013,In-kind items and services,311115566,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,40.00,10/16/2013,In-kind items and services,311115580,IMLYGIC,,P1b2 RP2 Study TVEC  and Yervoy,,
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,2750.00,12/13/2013,Cash or cash equivalent,342260600,,,EXCEL,,AV AV 10201280 20150603 0130 AV 10201280 20150603 0130 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,3000.00,12/13/2013,Cash or cash equivalent,342260606,,,EXCEL,,AV AV 10201280 20150603 0131 AV 10201280 20150603 0131 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,2750.00,12/13/2013,Cash or cash equivalent,342260610,,,EXCEL,,AV AV 10669432 20140110 0383 AV 10669432 20140110 0383 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,572,Catholic Health Initiatives Iowa Corp,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,3000.00,12/13/2013,Cash or cash equivalent,342260614,,,EXCEL,,AV AV 10669432 20140110 0384 AV 10669432 20140110 0384 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,580,Genesis Health System,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1000.00,09/18/2013,Cash or cash equivalent,342260128,,,CANOPY,,AV AV 10669432 20131021 0026 v2 AV 10669432 20131021 0026 0001 v2 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,2250.00,12/12/2013,Cash or cash equivalent,342261776,,,CANOPY,,AV AV 10201280 20140105 0129 v2 AV 10201280 20140105 0129 0001 v2 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,582,State University Of Iowa,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,3900.00,10/15/2013,Cash or cash equivalent,342261780,,,ACT I,,AV AV 10609214 20131122 0001 v2 AV 10609214 20131122 0001 0001 v2 Carotid Stenting vs Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic
Non-covered Recipient Entity,,,,,,,5880 University,,West Des Moines,50266,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,400.00,11/11/2013,Cash or cash equivalent,341783486,,,SPIRIT PRIME,,AV AV 10422247 20131213 0237 v2 AV 10422247 20131213 0237 0001 v2 SPIRIT PRIME Clinical Trial
Non-covered Recipient Entity,,,,,,,5880 University,,West Des Moines,50266,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,750.00,11/11/2013,Cash or cash equivalent,341783490,,,SPIRIT PRIME,,AV AV 10422247 20131213 0238 v2 AV 10422247 20131213 0238 0001 v2 SPIRIT PRIME Clinical Trial
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,3900.00,09/06/2013,Cash or cash equivalent,341783530,,,CANOPY,,AV AV 10609214 20131107 0086 v2 AV 10609214 20131107 0001 0001 v2 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2258.37,11/18/2013,In-kind items and services,327153214,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3763.95,08/30/2013,In-kind items and services,327152998,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35784.00,10/18/2013,In-kind items and services,327153010,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2258.37,08/30/2013,In-kind items and services,327152300,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26838.00,11/12/2013,In-kind items and services,327152316,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1505.58,09/27/2013,In-kind items and services,327153118,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
